AU2008317417A1 - Small molecule inhibitors of PARP activity - Google Patents
Small molecule inhibitors of PARP activity Download PDFInfo
- Publication number
- AU2008317417A1 AU2008317417A1 AU2008317417A AU2008317417A AU2008317417A1 AU 2008317417 A1 AU2008317417 A1 AU 2008317417A1 AU 2008317417 A AU2008317417 A AU 2008317417A AU 2008317417 A AU2008317417 A AU 2008317417A AU 2008317417 A1 AU2008317417 A1 AU 2008317417A1
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- oxo
- dihydrophthalazin
- amino
- methylpiperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title claims description 88
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title claims description 48
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 title claims description 46
- 230000000694 effects Effects 0.000 title claims description 41
- 239000003112 inhibitor Substances 0.000 title description 23
- 150000003384 small molecules Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 274
- -1 heteroaliphatic Chemical group 0.000 claims description 87
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 81
- 125000001072 heteroaryl group Chemical group 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 66
- 125000001931 aliphatic group Chemical group 0.000 claims description 60
- 201000010099 disease Diseases 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 51
- 125000002723 alicyclic group Chemical group 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 208000028867 ischemia Diseases 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 206010063837 Reperfusion injury Diseases 0.000 claims description 27
- 238000000338 in vitro Methods 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 230000005764 inhibitory process Effects 0.000 claims description 21
- 208000031225 myocardial ischemia Diseases 0.000 claims description 20
- 210000003734 kidney Anatomy 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 210000000056 organ Anatomy 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 201000006370 kidney failure Diseases 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- BVMFCBAKKWJCRA-UHFFFAOYSA-N 4-[3-amino-4-(4-methylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N BVMFCBAKKWJCRA-UHFFFAOYSA-N 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 210000002216 heart Anatomy 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 230000002107 myocardial effect Effects 0.000 claims description 8
- UEFIVSYVNGNMLY-UHFFFAOYSA-N 4-[3-amino-4-(4-ethylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound C1CN(CC)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N UEFIVSYVNGNMLY-UHFFFAOYSA-N 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- CMMZXOOUFMEUTH-UHFFFAOYSA-N 1-methyl-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound CNC(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C)CC1 CMMZXOOUFMEUTH-UHFFFAOYSA-N 0.000 claims description 6
- KYYWZVOHGLTBGZ-UHFFFAOYSA-N 4-(3-amino-4-piperazin-1-ylphenyl)-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCNCC1 KYYWZVOHGLTBGZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- 206010056328 Hepatic ischaemia Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 230000001133 acceleration Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000006938 muscular dystrophy Diseases 0.000 claims description 6
- ZZZYRTDFSHWCRE-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C(C)=O)CC1 ZZZYRTDFSHWCRE-UHFFFAOYSA-N 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 238000010606 normalization Methods 0.000 claims description 6
- 230000010412 perfusion Effects 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- QDEMDVOHTLYYPT-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]-1,3-benzodioxole-5-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1=CC=C(OCO2)C2=C1 QDEMDVOHTLYYPT-UHFFFAOYSA-N 0.000 claims description 5
- CFHLINZNBFTJPF-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(C)=O CFHLINZNBFTJPF-UHFFFAOYSA-N 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- GOUSPLIYOBEWLI-UHFFFAOYSA-N 2-chloro-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)CCl GOUSPLIYOBEWLI-UHFFFAOYSA-N 0.000 claims description 4
- VJCQOZJKZYVSPZ-UHFFFAOYSA-N 4-[3-amino-4-(4-benzylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1=CC=CC=C1 VJCQOZJKZYVSPZ-UHFFFAOYSA-N 0.000 claims description 4
- XUMAJNYDDYVYTK-UHFFFAOYSA-N 4-[3-amino-4-(4-cyclopentylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1C1CCCC1 XUMAJNYDDYVYTK-UHFFFAOYSA-N 0.000 claims description 4
- FOXPWXRFIRTKLD-UHFFFAOYSA-N 4-[3-amino-4-(4-cyclopropylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1C1CC1 FOXPWXRFIRTKLD-UHFFFAOYSA-N 0.000 claims description 4
- XUCAAVQBCRSLDS-UHFFFAOYSA-N 4-[3-amino-4-(4-propan-2-ylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound C1CN(C(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N XUCAAVQBCRSLDS-UHFFFAOYSA-N 0.000 claims description 4
- LLLKCWCNBMUQQX-UHFFFAOYSA-N 4-[3-amino-4-(4-tert-butylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound C1CN(C(C)(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N LLLKCWCNBMUQQX-UHFFFAOYSA-N 0.000 claims description 4
- RYVCIPMVGJJTRV-UHFFFAOYSA-N 4-[3-amino-4-[4-(pyridine-4-carbonyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1C(=O)C1=CC=NC=C1 RYVCIPMVGJJTRV-UHFFFAOYSA-N 0.000 claims description 4
- IBWNPBZFDVSMMS-UHFFFAOYSA-N 4-[3-amino-4-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound C1CN(CCN(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N IBWNPBZFDVSMMS-UHFFFAOYSA-N 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- XAZFYYLISQSZIN-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]cyclohexanecarboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1CCCCC1 XAZFYYLISQSZIN-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- BXQRVKVKUGALFR-UHFFFAOYSA-N 2,2-dimethyl-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]propanamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C(C)(C)C BXQRVKVKUGALFR-UHFFFAOYSA-N 0.000 claims description 3
- VNSPVMLPLMXYTG-UHFFFAOYSA-N 2-[4-[2-amino-4-(4-oxo-3h-phthalazin-1-yl)phenyl]piperazin-1-yl]acetic acid Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(CC(O)=O)CC1 VNSPVMLPLMXYTG-UHFFFAOYSA-N 0.000 claims description 3
- GTBBMNAIAKAHGB-UHFFFAOYSA-N 2-methyl-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C)CC1 GTBBMNAIAKAHGB-UHFFFAOYSA-N 0.000 claims description 3
- PYROIVLMTIYTDD-UHFFFAOYSA-N 3-cyano-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1=CC=CC(C#N)=C1 PYROIVLMTIYTDD-UHFFFAOYSA-N 0.000 claims description 3
- BBOXIUMATBIDOV-UHFFFAOYSA-N 4-[3-amino-4-(4-pyridin-4-ylpiperazin-1-yl)phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1C1=CC=NC=C1 BBOXIUMATBIDOV-UHFFFAOYSA-N 0.000 claims description 3
- HWLZNFAKTWVPAR-UHFFFAOYSA-N 4-[3-amino-4-[4-(2,5-dimethylphenyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound CC1=CC=C(C)C(N2CCN(CC2)C=2C(=CC(=CC=2)C=2C3=CC=CC=C3C(=O)NN=2)N)=C1 HWLZNFAKTWVPAR-UHFFFAOYSA-N 0.000 claims description 3
- IEBHLUXLZRGGIY-UHFFFAOYSA-N 4-[3-amino-4-[4-(2-aminophenyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC=CC=C1N1CCN(C=2C(=CC(=CC=2)C=2C3=CC=CC=C3C(=O)NN=2)N)CC1 IEBHLUXLZRGGIY-UHFFFAOYSA-N 0.000 claims description 3
- ZNYFCZNLBOSAGR-UHFFFAOYSA-N 4-[3-amino-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(CCO)CC1 ZNYFCZNLBOSAGR-UHFFFAOYSA-N 0.000 claims description 3
- POHGSYPORGONKW-UHFFFAOYSA-N 4-[3-amino-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound C1CN(CCOC)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N POHGSYPORGONKW-UHFFFAOYSA-N 0.000 claims description 3
- SKGRWAJBGDPSOY-UHFFFAOYSA-N 4-[3-amino-4-[4-(3-hydroxypropyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(CCCO)CC1 SKGRWAJBGDPSOY-UHFFFAOYSA-N 0.000 claims description 3
- POHSZFBUYRJPEJ-UHFFFAOYSA-N 4-[3-amino-4-[4-(cyclohexylmethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1CCCCC1 POHSZFBUYRJPEJ-UHFFFAOYSA-N 0.000 claims description 3
- IKWBINJDGNOGJQ-UHFFFAOYSA-N 4-[3-amino-4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1CC1 IKWBINJDGNOGJQ-UHFFFAOYSA-N 0.000 claims description 3
- RKTCYYQPQLNDGN-UHFFFAOYSA-N 4-[3-amino-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1=CC=CN=C1 RKTCYYQPQLNDGN-UHFFFAOYSA-N 0.000 claims description 3
- LUAFVVBZHCFCCJ-UHFFFAOYSA-N 4-[3-amino-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1=CC=NC=C1 LUAFVVBZHCFCCJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010029113 Neovascularisation Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- LHWBZLGTGNVZTM-UHFFFAOYSA-N n-[2-(4-tert-butylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(C(C)(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C(C)(C)C LHWBZLGTGNVZTM-UHFFFAOYSA-N 0.000 claims description 3
- VZPQBVVQRUYCFX-UHFFFAOYSA-N n-[2-(4-tert-butylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C(C)(C)C)CC1 VZPQBVVQRUYCFX-UHFFFAOYSA-N 0.000 claims description 3
- SCAVPMRFHONCNO-UHFFFAOYSA-N n-[5-(4-oxo-3h-phthalazin-1-yl)-2-(4-propan-2-ylpiperazin-1-yl)phenyl]acetamide Chemical compound C1CN(C(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(C)=O SCAVPMRFHONCNO-UHFFFAOYSA-N 0.000 claims description 3
- LESLBEILMFGNTF-UHFFFAOYSA-N n-[[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]carbamoyl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)NC(=O)C1=CC=CC=C1 LESLBEILMFGNTF-UHFFFAOYSA-N 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- GSATZNLOGSPWDF-UHFFFAOYSA-N 1-cyclopentyl-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)NC1CCCC1 GSATZNLOGSPWDF-UHFFFAOYSA-N 0.000 claims description 2
- KTLAFVICSDLQIP-UHFFFAOYSA-N 1-ethyl-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound CCNC(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C)CC1 KTLAFVICSDLQIP-UHFFFAOYSA-N 0.000 claims description 2
- AYBAKSAOZITBQO-UHFFFAOYSA-N 1-tert-butyl-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)NC(C)(C)C AYBAKSAOZITBQO-UHFFFAOYSA-N 0.000 claims description 2
- AFLYMUXXEWZLRE-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)CC1=CC=C(Cl)C=C1 AFLYMUXXEWZLRE-UHFFFAOYSA-N 0.000 claims description 2
- MWVACIGOHOWLCW-UHFFFAOYSA-N 2-methoxy-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound COCC(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C)CC1 MWVACIGOHOWLCW-UHFFFAOYSA-N 0.000 claims description 2
- MICFSZDVHSGZFC-UHFFFAOYSA-N 3-[4-[2-amino-4-(4-oxo-3h-phthalazin-1-yl)phenyl]piperazin-1-yl]propanenitrile Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(CCC#N)CC1 MICFSZDVHSGZFC-UHFFFAOYSA-N 0.000 claims description 2
- GSQQOQJHFDZZPZ-UHFFFAOYSA-N 3-methoxy-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC=C(C=2)C=2C3=CC=CC=C3C(=O)NN=2)N2CCN(C)CC2)=C1 GSQQOQJHFDZZPZ-UHFFFAOYSA-N 0.000 claims description 2
- ZENIQSDGQLMXMT-UHFFFAOYSA-N 4-[3-amino-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound C1CN(C)CCC1N1CCN(C=2C(=CC(=CC=2)C=2C3=CC=CC=C3C(=O)NN=2)N)CC1 ZENIQSDGQLMXMT-UHFFFAOYSA-N 0.000 claims description 2
- UDIXQGHVCYUDGB-UHFFFAOYSA-N 4-[3-amino-4-[4-(3-methoxyphenyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound COC1=CC=CC(N2CCN(CC2)C=2C(=CC(=CC=2)C=2C3=CC=CC=C3C(=O)NN=2)N)=C1 UDIXQGHVCYUDGB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- MDBPIRDDHFAOCH-UHFFFAOYSA-N methyl 2-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)anilino]-2-oxoacetate Chemical compound COC(=O)C(=O)NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(C)CC1 MDBPIRDDHFAOCH-UHFFFAOYSA-N 0.000 claims description 2
- KXUJXJWGJLVUQR-UHFFFAOYSA-N n-[2-(4-ethylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(CC)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C(C)(C)C KXUJXJWGJLVUQR-UHFFFAOYSA-N 0.000 claims description 2
- VBWGBVLTCRPTQS-UHFFFAOYSA-N n-[2-(4-ethylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]acetamide Chemical compound C1CN(CC)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(C)=O VBWGBVLTCRPTQS-UHFFFAOYSA-N 0.000 claims description 2
- WIAXAAQZISUTAA-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]-2-phenylacetamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)CC1=CC=CC=C1 WIAXAAQZISUTAA-UHFFFAOYSA-N 0.000 claims description 2
- NQPWFMDPTVFURG-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]-2-thiophen-2-ylacetamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)CC1=CC=CS1 NQPWFMDPTVFURG-UHFFFAOYSA-N 0.000 claims description 2
- LAWXIEXYZSADGV-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1CC1 LAWXIEXYZSADGV-UHFFFAOYSA-N 0.000 claims description 2
- XRGHNZRCVBIMED-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C=C XRGHNZRCVBIMED-UHFFFAOYSA-N 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- QHUSOTVNRQZPOV-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)NC1=CC=C(F)C=C1 QHUSOTVNRQZPOV-UHFFFAOYSA-N 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 48
- 238000011282 treatment Methods 0.000 description 45
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 125000001424 substituent group Chemical group 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 230000010410 reperfusion Effects 0.000 description 13
- 229960004964 temozolomide Drugs 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010018338 Glioma Diseases 0.000 description 11
- 125000002877 alkyl aryl group Chemical group 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 239000012049 topical pharmaceutical composition Substances 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 208000032612 Glial tumor Diseases 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000036365 BRCA1 Human genes 0.000 description 6
- 108700020463 BRCA1 Proteins 0.000 description 6
- 101150072950 BRCA1 gene Proteins 0.000 description 6
- 102000052609 BRCA2 Human genes 0.000 description 6
- 108700020462 BRCA2 Proteins 0.000 description 6
- 101150008921 Brca2 gene Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000004405 heteroalkoxy group Chemical group 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 125000005368 heteroarylthio group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
- RITAQDHCJBLSSL-UHFFFAOYSA-N 2-(4-chloro-3-nitrobenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 RITAQDHCJBLSSL-UHFFFAOYSA-N 0.000 description 4
- 230000005730 ADP ribosylation Effects 0.000 description 4
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010038540 Renal tubular necrosis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical group CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- YHDJIHYJPQZDFP-UHFFFAOYSA-N methyl 2-(4-chloro-3-nitrobenzoyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 YHDJIHYJPQZDFP-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 4
- XIPFMBOWZXULIA-UHFFFAOYSA-N pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- WBQPJNQIXPQTOV-UHFFFAOYSA-N 2-[3-amino-4-(4-ethylpiperazin-1-yl)benzoyl]benzoic acid Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)C=2C(=CC=CC=2)C(O)=O)C=C1N WBQPJNQIXPQTOV-UHFFFAOYSA-N 0.000 description 3
- BEGMIMROGRGKKS-UHFFFAOYSA-N 2-[4-(4-ethylpiperazin-1-yl)-3-nitrobenzoyl]benzoic acid Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)C=2C(=CC=CC=2)C(O)=O)C=C1[N+]([O-])=O BEGMIMROGRGKKS-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 231100001074 DNA strand break Toxicity 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010063897 Renal ischaemia Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 3
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- LPMLGMZQNDYGBH-UHFFFAOYSA-N methyl 2-(3-amino-4-piperazin-1-ylbenzoyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)C(C=C1N)=CC=C1N1CCNCC1 LPMLGMZQNDYGBH-UHFFFAOYSA-N 0.000 description 3
- DIOFTCINUGIDNN-UHFFFAOYSA-N methyl 2-(3-nitro-4-piperazin-1-ylbenzoyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)C(C=C1[N+]([O-])=O)=CC=C1N1CCNCC1 DIOFTCINUGIDNN-UHFFFAOYSA-N 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000006540 mitochondrial respiration Effects 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000009038 pharmacological inhibition Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical group CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- NCMQQPWUDBTGIO-UHFFFAOYSA-N tert-butyl 2-[4-[2-amino-4-(4-oxo-3h-phthalazin-1-yl)phenyl]piperazin-1-yl]acetate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1N NCMQQPWUDBTGIO-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VRQOTWASTOWRNQ-UHFFFAOYSA-N 1-cyclohexyl-3-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]urea Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)NC1CCCCC1 VRQOTWASTOWRNQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- ZYPUXGWCBRLMEG-UHFFFAOYSA-N 3-[4-[2-amino-4-(4-oxo-3h-phthalazin-1-yl)phenyl]piperazin-1-yl]propanoic acid Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N1CCN(CCC(O)=O)CC1 ZYPUXGWCBRLMEG-UHFFFAOYSA-N 0.000 description 2
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- WWRAFPGUBABZSD-UHFFFAOYSA-N 6-amino-5-iodochromen-2-one Chemical compound O1C(=O)C=CC2=C(I)C(N)=CC=C21 WWRAFPGUBABZSD-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 206010000591 Acrochordon Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010004950 Birth mark Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000033640 Hereditary breast cancer Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000992283 Homo sapiens Optineurin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 102100031822 Optineurin Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108091026813 Poly(ADPribose) Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 201000007180 bile duct carcinoma Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 2
- 229950009823 calusterone Drugs 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- NTYSMQLKONZLPO-UHFFFAOYSA-N methyl 2-[3-amino-4-(4-methylpiperazin-1-yl)benzoyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)C(C=C1N)=CC=C1N1CCN(C)CC1 NTYSMQLKONZLPO-UHFFFAOYSA-N 0.000 description 2
- MUOZFWSFUDKFKB-UHFFFAOYSA-N methyl 2-[4-(4-methylpiperazin-1-yl)-3-nitrobenzoyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)C(C=C1[N+]([O-])=O)=CC=C1N1CCN(C)CC1 MUOZFWSFUDKFKB-UHFFFAOYSA-N 0.000 description 2
- 150000005217 methyl ethers Chemical class 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960003753 nitric oxide Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 208000024724 pineal body neoplasm Diseases 0.000 description 2
- 201000004123 pineal gland cancer Diseases 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- 230000005731 poly ADP ribosylation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108010084837 rasburicase Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- ZRSGZIMDIHBXIN-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OCOC2=C1 ZRSGZIMDIHBXIN-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- UUAKOKFSMXRGJP-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethoxymethoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCOCOCC1=CC=C(OC)C=C1 UUAKOKFSMXRGJP-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZVTDEEBSWIQAFJ-KHPPLWFESA-N 2-hydroxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-KHPPLWFESA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- KBSDLBVPAHQCRY-UHFFFAOYSA-N 307496-19-1 Chemical group C1CC=CCC1CC[Si](O1)(O2)O[Si](O3)(C4CCCC4)O[Si](O4)(C5CCCC5)O[Si]1(C1CCCC1)O[Si](O1)(C5CCCC5)O[Si]2(C2CCCC2)O[Si]3(C2CCCC2)O[Si]41C1CCCC1 KBSDLBVPAHQCRY-UHFFFAOYSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- IKACFGXJOVQBLH-UHFFFAOYSA-N 4-[3-amino-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2H-phthalazin-1-one 4-[3-amino-4-[4-(oxolan-2-ylmethyl)piperazin-1-yl]phenyl]-2H-phthalazin-1-one Chemical compound NC=1C=C(C=CC1N1CCN(CC1)CCOC)C1=NNC(C2=CC=CC=C12)=O.NC=1C=C(C=CC1N1CCN(CC1)CC1OCCC1)C1=NNC(C2=CC=CC=C12)=O IKACFGXJOVQBLH-UHFFFAOYSA-N 0.000 description 1
- SFODAMCIZRCRCI-UHFFFAOYSA-N 4-[3-amino-4-[4-(oxolan-2-ylmethyl)piperazin-1-yl]phenyl]-2h-phthalazin-1-one Chemical compound NC1=CC(C=2C3=CC=CC=C3C(=O)NN=2)=CC=C1N(CC1)CCN1CC1CCCO1 SFODAMCIZRCRCI-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- LGUCXNVHPBJSFW-UHFFFAOYSA-N 4-fluoro-n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1=CC=C(F)C=C1 LGUCXNVHPBJSFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- FMXSYRBHGUMFBA-UHFFFAOYSA-N 6-amino-3-azaniumylidene-9-[2-carboxy-4-[6-[4-[4-[4-[4-[3-carboxy-6-[4-(trifluoromethyl)phenyl]naphthalen-1-yl]phenyl]piperidin-1-yl]butyl]triazol-1-yl]hexylcarbamoyl]phenyl]-5-sulfoxanthene-4-sulfonate Chemical compound Nc1ccc2c(-c3ccc(cc3C(O)=O)C(=O)NCCCCCCn3cc(CCCCN4CCC(CC4)c4ccc(cc4)-c4cc(cc5cc(ccc45)-c4ccc(cc4)C(F)(F)F)C(O)=O)nn3)c3ccc(=[NH2+])c(c3oc2c1S(O)(=O)=O)S([O-])(=O)=O FMXSYRBHGUMFBA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101710155556 Calcium-dependent protease Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710148289 DNA ligase 2 Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000021709 Delayed Graft Function Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical class CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000684297 Homo sapiens 26S proteasome complex subunit SEM1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 description 1
- 101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 description 1
- 101000873438 Homo sapiens Putative protein SEM1, isoform 2 Proteins 0.000 description 1
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000904868 Homo sapiens Transcriptional regulator ATRX Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102100034920 Putative protein SEM1, isoform 2 Human genes 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108010017601 Tankyrases Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229940041983 daunorubicin liposomal Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940098617 ethyol Drugs 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229940101533 mesnex Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- BSPHISPAWGWTGS-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)-5-(4-oxo-3h-phthalazin-1-yl)phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=CC=CC=C3C(=O)NN=2)C=C1NC(=O)C1=CC=CO1 BSPHISPAWGWTGS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229940098901 polifeprosan 20 Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940053186 sclerosol Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940111100 tice bcg Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940001814 uvadex Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229940053890 zanosar Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 2009/054952 PCT/US2008/011990 SMALL MOLECULE INHIBITORS OF PARP ACTIVITY BACKGROUND OF THE INVENTION [00011 Poly ADP-ribose synthetase 1 (or PARP-1) is a dimeric nuclear protein, with two 113 kDa polypeptide subunits, each consisting of three functional domains: the DNA binding amino 5 terminal domain with two zinc fingers for recognition of single and double strand DNA breaks, such as those induced by reactive oxygen species (ROS), gamma-irradiation and DNA alkylating agents, the central automodification domain (auto ADP-ribosylation), and the carboxyl terminus catalytic domain, using NAD+ as substrate, for the synthesis of the ADP-ribose polymers, which vary in length between 50-200 subunits. Other family members, all of which share high 10 homology to PARP-1 in the amino and carboxyl termini are PARP-2, 3, vault-PARP and tankyrase. In addition to autocatalytic ADP-ribosylation, PARP-1 has been shown to use histones, topoisomerase I and II, DNA polymerases, and DNA ligase 2 as protein acceptors. This poly ADP-ribosylation appears to inhibit the activity of some of the enzymes, but for histones the ADP-ribosylation has been proposed to stimulate chromosome relaxation allowing 15 for DNA repair. In fact, a requirement for PARP- 1 in the recovery from DNA damage induced by N-methyl-N-nitrosourea (MNU) and gamma-radiation was demonstrated using PARP deficient mice and embryo fibroblasts. 100021 Importantly, reactive oxygen species (ROS) have been shown to mediate over activation of PARP-1, which has been demonstrated to cause critical ATP depletion leading to 20 cell necrosis, as the toxic effects can be substantially ameliorated by either: PARP-1 inhibitors in the cell lineages; macrophages, aortic smooth muscle, neuronal and endothelial, or absence of active PARP-1 in PARP-1-/- deficient fibroblasts. [0003] In addition to the role of PARP-1 in a housekeeping, general genome maintenance function, there is more recent evidence for a role of PARP-1 in specific gene expression, 25 particularly through interaction with Nf-KB. Importantly in the context of ischemia-reperfusion (IR) injury, target genes of Nf-KB in endothelial cells include inducible nitric-oxide synthase (iNOS) and the cell adhesion molecules P-selectin and intracellular adhesion molecule-1 (ICAM-1). Nitric oxide (NO), which is known to have potent vasodilating activity may act as a protective factor during IR injury, however under in the presence of superoxide, endogenous NO 30 has been shown to be detrimental to the health of the IR injured tissues, possibly due to the synthesis of peroxynitrite. In turn, the cell surface expression of P-selectin and ICAM- 1 has been shown to mediate the tissue infiltration of neutrophils, which has been demonstrated to 1 WO 2009/054952 PCT/US2008/011990 contribute to -IR-mediated organ damage. PARP-1 deficient mice have been shown to be resistant to the ischemia reperfusion injury of the heart, which is associated with reduced level of ICAM-1 and P-selectin expression in the vascular endothelium and injured myocytes of the myocardium and corresponding neutrophil recruitment induced by Ischemia-reperfusion. 5 [00041 Several studies of the use of pharmacological inhibitors of PARP-1 in vivo have demonstrated efficacy in reducing IR induced tissue damage, and improved function of the heart, skeletal muscle, liver and arthritic joints. In a rabbit model, PARP-1 inhibitors significantly decreased infarct size in the heart due to 45-minute occlusion and two-hour reperfusion, as well as skeletal muscle necrosis due to a two-hour occlusion and four-hour reperfusion. In a study of 10 liver microcirculation and function after hemorrhagic shock and resuscitation in rats, the PARP 1 inhibitor 5-aminoisoquinoline (5-AIQ), demonstrating decreased leukocyte-endothelial interaction, decreased liver injury and improved liver function. Also, in a mouse model of arthritis, the PARP-1 inhibitor 5-iodo-6-amino-1,2-benzopyrone (INH2BP) reduced the severity of the disease as assessed by the histological parameters; inflammatory cell infiltration, 15 hyperplasia of the synovium and tissue necrosis. [0005] Several studies in animal models of ischemia-reperfusion have been performed specifically to elucidate the possible role of over-activated PARP-1 in the tissue injury. In a mouse model of thoracoabdominal aneurysm mediated renal injury, the potent PARP- 1 inhibitor PJ34 was used to determine the possible role of PARP-1 in this setting. Mice were exposed to 20 eleven minutes of aortic ischemia followed by 48 hours of reperfusion, and were treated with PJ34 Ihour before and immediately after the ischemic period. PJ34 was shown to preserve renal mitochondrial activity and decrease steady state levels of a marker for neutrophil infiltration, but had no apparent affect on fibrinolysis stimulated by the ischemia-reperfusion. Studies in a rat model of direct renal ischemia induced by occluding the renal arteries, demonstrated that the 25 PARP-1 inhibitors 3-aminobenzamide (3-AB) and 1,5-dihroxyisoquinoline improved kidney function as measured by blood and urine markers, plasma urea, plasma creatinine and glomerular filtration rate following 45 minutes of ischemia and up to six hours of reperfusion, with the experimental drugs given one minute before reperfusion. Finally, in the study of PARP-1 expression in human transplant recipients between days 5 and 11 of post-transplantation, all with 30 acute tubular necrosis; PARP-l expression correlated with the duration of cold renal ischemia, with its expression being highest after ten hours and correlating significantly with delayed renal function. 2 WO 2009/054952 PCT/US2008/011990 [0006] Familial breast and ovarian cancers, which account for 5-10% of these cancers, are commonly caused by the inherited defect in one of the BRCA1 or BRCA2 alleles. During life the normal, functional BRCA1 or BRCA2 alleles can be lost in some cells, thus initiating the development of a tumor. The tumors that developed were BRCA1 or BRCA2 deficient while 5 remaining somatic cells had functional BRCA proteins. As described above, such tumor cells would be expected to be extremely sensitive to PARP-1 inhibition and this has been confirmed recently. Two independent groups demonstrated specific killing of BRCA deficient cells and inhibition of tumor xenograft growth by pharmacological inhibition of PARP-1 alone with no requirement to combine with chemotherapy. In addition cells deficient in other gene products 10 responsible for homologous recombination such as RAD51, RAD54, DSS1, RPA1, NBSI ATM, ATR CHK1, FANCD2, FANCA or FANCC, are also sensitive to PARP-1 inhibition. [0007] Alternatively, for the majority of neoplasias, which are not deficient in HR function; the combination of DNA damaging agents (chemotherapy or radiation treatment) with PARP-1 inhibition would be expected to mimic the PARP-1 deficient animal studies and increase the 15 tumor's sensitivity to the DNA damaging agent, and this has been the case. Synergistic tumor cell killing has been demonstrated using a PARP- 1 inhibitor in combination with camptothecin, a topoisomerase I inhibitor; with the PARP-1 inhibitor increasing cytotoxicity and DNA strand breaks in parallel, 2.5 fold. Consistent with this, camptothecin alone induced DNA strand breaks that lead to a four-fold activation of PARP-1. Interestingly, etoposide, a topoisomerase II 20 inhibitor, induced DNA strand breaks but failed to induce PARP-1 or synergize with the PARP-1 inhibitor in cytotoxicity. Similarly, PARP- 1 deficient V79 cells were shown to be hypersensitive to topoisomerase I inhibitors but resistant to etoposide. Also, PARP-1 inhibitors could not potentiate the cytotoxicity of cisplatin in ovarian tumor cells, again suggesting specificity to the type of strand breaks. Several studies have shown the potentiation of temozolomide (TMZ) by 25 PARP-1 inhibitors. Studies have demonstrated the potentiation (1.2-5 fold) of TMZ growth inhibition and cytotoxicity by PARP-1 pharmacological inhibition across many tumor cell lines representing lung, ovarian, colon and breast cancers (gliomas not tested in their system). PARP-1 inhibition was shown to increase the antitumor activity of TMZ against intracranial melanoma, lymphoma, and glioma in vivo using murine orthotopic, tumor models; demonstrating improved 30 survival of tumor bearing mice and an increase in anti-metastatic effect of TMZ. Also, other studies have shown that PARP-1 inhibition increased the antiproliferative effect of TMZ in colorectal cancer cell line LoVo by 5.5 fold, and decreased recovery from gamma-radiation damage in this cell line by 75%. In vivo, a non-toxic dose of this inhibitor increased the delay of 3 WO 2009/054952 PCT/US2008/011990 LoVo xenograft growth induced by irinotecan, TMZ and x-irradiation by two- to threefold. Interestingly, increased antitumor activity was demonstrated from PARP-1 inhibition with TMZ in another colorectal line, SW620 xenografts while no such activity was demonstrated in vitro. Further analysis demonstrated PARP- 1 inhibition statistically, significantly increased blood flow 5 to the tumor and thus possibly increased TMZ delivery to the SW620 xenografts. This possible utility of PARP-1 inhibitors in cancer therapy has been described earlier for the less potent PARP- 1 inhibitor nicotinamide, which had been shown to inhibit contraction of vascular smooth muscle cells in tumors. Activation of the transcription factor, NF-KB which has been shown in many tumor cell lines, including glioma, in vitro and in vivo to promote cell survival, 10 proliferation, angiogenesis and metastasis, by transcriptional activation of antiapoptotic genes (e.g., cIAP, survivin, Bcl-2 and Bcl-Xl) cell cycle regulatory genes (cyclin D1 and c-myc) COX-2, matrix meltalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF). As described above, the role of PARP-1 in activation of NF-B and the benefit of inhibitors of PARP- 1 activity also have relevance in cancer therapy. 15 [00081 In certain embodiments, the present invention is directed toward the identification of small organic molecules that exhibit PARP inhibitory activity and are thus useful in the treatment or prevention of conditions or diseases in which inhibition of PARP is desirable. [0009] All citations in the present application are incorporated herein by reference in their entireties. The citation of any reference herein should not be construed as an admission that such 20 reference is available as "Prior Art" to the instant application. SUMMARY OF THE INVENTION [0010] As discussed above, there remains a need for the development of novel therapeutics that inhibit PARP activity. [0011] In one embodiment, certain novel inventive compounds have the structure shown in 25 Formula (I) below:
R
2 RIN
R
3 -N \/ N O I or a pharmaceutically acceptable salt thereof; 4 WO 2009/054952 PCT/US2008/011990 wherein R' and R 2 are independently H or COR 4 ;
R
3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and
R
4 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, 5 heterocyclic, aromatic, or heteroaromatic moiety. [0012] In another embodiment, certain novel inventive compounds have the structure shown in Formula (II) below: R4 HN
R
3 -N N 0 N-NH II 10 or a pharmaceutically acceptable salt thereof; wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and wherein R 4 is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety. 15 [0013] In still another embodiment, certain novel inventive compounds have the structure shown in Formula (III) below:
R
6
R
5 N )=o HN
R
3 -N N O N-N N-NH III or a pharmaceutically acceptable salt thereof; 20 wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and
R
5 and R6 are each independently an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety; or R 5 and R6 can be joined together to form a ring; or one of R5 and R6 is H. 5 WO 2009/054952 PCT/US2008/011990 [0014] In still another embodiment, certain novel inventive compounds have the structure shown in Formula (IV) below:
H
2 N
R
3 -N N O N-NH IV 5 or a pharmaceutically acceptable salt thereof; and wherein R3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety. [00151 In another aspect, the invention is directed to compositions including pharmaceutical compositions comprising of any of the compounds disclosed herein. 10 [0016] In another aspect, the invention provides methods for the use of any of the compounds disclosed herein for inhibiting PARP activity in a patient or a biological sample. The compounds and pharmaceutical compositions of the invention have the activity of inhibiting PARP and are useful in the treatment of any disease, disorder or condition in which inhibition of PARP activity would be useful. 15 [0017] In another aspect, the invention provides methods for the use of any of the compounds disclosed herein for treating or lessening the severity of a disease, disorder or condition associated with PARP activity. Such diseases, disorders and conditions include, but are not limited to, muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, damaged and/or ischemic organs, transplants or grafts; 20 ischemia/reperfusion injury; stroke, traumatic head injury, spinal cord injury, and other cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; other cardiovascular diseases; diabetes; renal failure; multiple sclerosis; and neurodegenerative diseases such as Parkinsonism and Alzheimer disease. In certain exemplary embodiments, the method is for the treatment of wounds for acceleration of healing; amelioration of 25 ischemia/reperfusion injury in the brain, heart, liver, kidney, or other tissues or organs; normalization of myocardial perfusion as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus. Use of the compound is also provided for prophylaxis or preventing the occurrence of the diseases in subjects, and in particular subjects susceptible to of exhibiting risk 30 factors for, the aforementioned diseases and conditions. 6 WO 2009/054952 PCT/US2008/011990 [0018] Furthermore, compounds embodied herein are also useful for the treatment of various dysproliferative diseases and in particular for potentiating the activity of chemotherapeutic agents against dysproliferative diseases. Such dysproliferative diseases include but are not limuted to various cancers, as well as inflammatory disease in particular where inflammation, 5 especially chronic inflammation, leads to inappropriate vascularization. Examples of cancers, tumors, malignancies, neoplasms, and other dysproliferative diseases that can be treated according to the invention include leukemias, such as myeloid and lymphocytic leukemias, lymphomas, myeloproliferative diseases, and solid tumors, such as but not limited to sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic 10 sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, 15 cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, 20 meningioma, melanoma, neuroblastoma, and retinoblastoma. In preferred but non-limiting embodiments, brain tumors, including glioma, and pancreatic cancers are amenable to treatment by the compounds of the present invention. [00191 The invention also provides methods for the use of any of the compounds disclosed herein for use as adjuvant therapy with DNA-damaging chemotherapeutics for treatment of 25 various forms of cancer including but not limited melanoma, breast, ovarian and glioblastoma and in treatment of HIV infection. Use of the compound is also provided for prophylaxis or preventing the occurrence of the diseases in subjects, and in particular subjects susceptible to of exhibiting risk factors for, the aforementioned diseases and conditions. [0020] Examples of inflammatory diseases toward which compounds of the invention have 30 benefit include rheumatoid arthritis, atherosclerosis, and neovascularization in the eye as a consequence of diabetic retinopathy. [0021] The present invention is also directed to treatment of non-malignant tumors and other disorders involving inappropriate cell or tissue growth by administering a therapeutically 7 WO 2009/054952 PCT/US2008/011990 effective amount of an agent of the invention. For example, the invention is useful for the treatment of arteriovenous (AV) malformations, particularly in intracranial sites. The invention can also be used to treat psoriasis, a dermatologic condition that is characterized by inflammation and vascular proliferation; benign prostatic hypertrophy, a condition associated 5 with inflammation and possibly vascular proliferation; and cutaneous fungal infections. Treatment of other hyperproliferative disorders is also embraced herein. The agents may also be used topically to remove warts, birthmarks, moles, nevi, skin tags, lipomas, angiomas including hemangiomas, and other cutaneous lesions for cosmetic or other purposes. [0022] In another embodiment, a method is provided that comprises the step of 10 administering to a subject suffering from a disease or condition associated with PARP activity an effective amount of a compound of any one of formulas (I) - (IV) or a composition thereof; wherein the compound is characterized by its ability to inhibit PARP activity. In a further embodiment, the disease or condition can be muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, damaged and/or ischemic organs, transplants 15 or grafts; ischemia/reperfusion injury; stroke, traumatic head injury, spinal cord injury, and other cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; other cardiovascular diseases; diabetes; renal failure; multiple sclerosis; and neurodegenerative diseases such as Parkinsonism and Alzheimer disease. In certain exemplary embodiments, the method is for the treatment of wounds for acceleration of healing; amelioration of 20 ischemia/reperfusion injury in the brain, heart, liver, kidney, or other tissues or organs; normalization of myocardial perfusion as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus. In other embodiments the disease or condition is a dysproliferative disease such as cancer. In another embodiment the disease is an inflammatory disease. In another 25 embodiment, the compound inhibits PARP with an in vitro IC 50 of about 1 to about 5 micromolar. In another embodiment, the compound inhibits PARP with an in vitro IC 50 of about 0.1 to about 1 micromolar. In another embodiment, the compound inhibits PARP with an in vitro
IC
50 of about 0.001 to about 0.1 micromolar. In another embodiment the compound inhibits PARP with an in vitro IC 50 of more than about 0.001 micromolar. In another embodiment, the 30 compound inhibits PARP with an in vitro ICso of about 0.001 micromolar. 8 WO 2009/054952 PCT/US2008/011990 BRIEF DESCRIPTIONS OF THE FIGURES [0023] Figure 1 shows the results of a PARP-1 inhibition dose response curve with an exemplary compound, compared to positive control compound PJ34. [00241 Figure 2 shows the inhibition of hydrogen peroxide-induced ATP depletion by an 5 exemplary compound. [0025] Figure 3 A-D shows the inhibition of brain PAR after an exemplary compound is administered intravenously. [0026] Figure 4 shows the reduction in brain infarct zone size by administration of an exemplary compound in a stroke model, either at the time of induction or after a delay of 4 10 hours. DEFINITIONS [0027] It is understood that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term "substituted" whether preceded by the term "optionally" or not, and substituents contained in formulas of this 15 invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible 20 substituents include acyclic and cyclic, branched and unbanked, carbocyclic and heterocyclic, aromatic and non-aromatic, carbon and heteroatom substituents of organic compounds. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Furthermore, this invention is not intended to be limited in any manner by 25 the permissible substituents of organic compounds. Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment and prevention, for example of disorders, as described generally above. Examples of substituents include, but are not limited to aliphatic; heteroaliphatic; alicyclic; heterocyclic; aromatic, heteroaromatic; aryl; heteroaryl; alkylaryl; aralkyl; alkylheteroaryl; 30 alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -NO 2 ; -CN; -CF 3 ; -CH 2
CF
3 ; -CHC1 2 ; -CH 2 OH; -CH 2
CH
2 OH; -CH 2
NH
2 ; CH 2
SO
2
CH
3 ; or -GRG' wherein G is -0-, -S-, -NRG 2 -, -C(=O)-, -S(=0)-, -SO 2 -, -C(=0)O-, 9 WO 2009/054952 PCT/US2008/011990
C(=O)NRG
2 -, -OC(=O)-, -NRG 2 C(=O)-, -OC(=O)O-, -OC(=O)NRG 2 -, -NRG 2 C(=O)O, _ NR2C(=O)NRG 2 -, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG 2 )-, -C(=NR G2)_, _
C(=NRG
2
)NRG
3 -, -OC(=NRG 2 )-, -NRG 2
C(=NRG
3 )-, -NRG 2
SO
2 -, -NRG 2
SO
2
NRG
3 -, or -SO 2
NRG
2 _, wherein each occurrence of RG 1 , RG 2 and RG' independently includes, but is not limited to, 5 hydrogen, halogen, or an optionally substituted aliphatic, heteroaliphatic, alicyclic, heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0028] The term "stable", as used herein, preferably refers to compounds which possess 10 stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein. [0029] The term "aliphatic", as used herein, includes both saturated and unsaturated, straight chain (i.e., unbranched) or branched aliphatic hydrocarbons as defined by IUPAC, which are 15 optionally substituted with one or more functional groups. As defined herein, "aliphatic" is intended to include optionally substituted alkyl, alkenyl and alkynyl moieties. Thus, as used herein, the term "alkyl" includes straight and branched alkyl groups. An analogous convention applies to other generic terms such as "alkenyl", "alkynyl" and the like. Furthermore, as used herein, the terms alkyll", "alkenyl", "alkynyl" and the like encompass both substituted and 20 unsubstituted groups. In certain embodiments, as used herein, "lower alkyl" is used to indicate those alkyl groups (substituted, unsubstituted, branched or unbranched) having about 1-6 carbon atoms. In some instances aliphatic can include alicyclic or cycloalkyl, including unsaturations therein. [0030] In certain embodiments, the alkyl, alkenyl and alkynyl groups employed in the 25 invention contain 1-20; 2-20; 3-20; 4-20; 5-20; 6-20; 7-20 or 8-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10; 2-10; 3-10; 4-10; 5-10; 6-10; 7-10 or 8-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8; 2-8; 3-8; 4-8; 5-8; 6-20 or 7-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, 30 and alkynyl groups employed in the invention contain 1-6; 2-6; 3-6; 4-6 or 5-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4; 2-4 or 3-4 carbon atoms. Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, allyl, n-butyl, sec-butyl, isobutyl, 10 WO 2009/054952 PCT/US2008/011990 tert-butyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, n-hexyl, sec-hexyl, moieties and the like, which again, may bear one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and 5 the like. [00311 The term "alicyclic", as used herein, refers to compounds that combine the properties of aliphatic and cyclic compounds and include but are not limited to cyclic, or polycyclic aliphatic hydrocarbons and bridged cycloalkyl compounds, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, 10 "alicyclic" is intended herein to include, but is not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, which are optionally substituted with one or more functional groups. Illustrative alicyclic groups thus include, but are not limited to, for example, cyclopropyl,
-CH
2 -cyclopropyl, cyclobutyl, -CH 2 -cyclobutyl, cyclopentyl, -CH 2 -cyclopentyl-n, cyclohexyl,
-CH
2 -cyclohexyl, cyclohexenylethyl, cyclohexanylethyl, norborbyl moieties and the like, which 15 again, may bear one or more substituents. [00321 The term "cycloalkyl", as used herein, refers to cyclic alkyl groups, specifically to groups having three to seven, preferably three to ten carbon atoms. Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of aliphatic, heteroaliphatic or heterocyclic moieties, may optionally be 20 substituted. An analogous convention applies to other generic terms such as "cycloalkenyl", "cycloalkynyl" and the like. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0033] The term "heteroaliphatic", as used herein, refers to aliphatic moieties in which one or more carbon atoms in the main chain have been replaced with a heteroatom. Thus, a 25 heteroaliphatic group refers to an aliphatic chain which contains one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms in place of carbon atoms in the aliphatic main chain. Heteroaliphatic moieties may be branched or linear unbranched. In certain embodiments, heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; 30 heteroaliphatic; alicyclic; heterocyclic; aromatic, heteroaromatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -NO 2 ; -CN; -CF 3 ; -CH 2
CF
3 ; -CHC1 2 ; -CH 2 OH;
-CH
2
CH
2 OH; -CH 2
NH
2 ; -CH 2
SO
2
CH
3 ; or -GRGI wherein G is -0-, -S-, -NRG 2 _, -C(=O)-, 11 WO 2009/054952 PCT/US2008/011990 -S(=O)-, -SO 2 -, -C(=O)O-, -C(=O)NRG 2 -, -OC(=O)-, -NRG 2 C(=O)-, -OC(=O)O-, -OC(=O)NRG 2 _
-NRG
2 C(=O)O-, -NRG 2
C(=O)NRG
2 -, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG 2 )_,
-C(=NRG
2 )O-, -C(=NRG 2
)NRG
3 -, -OC(=NRG 2 )-, -NRG 2
C(=NRG
3 )-, -NRG 2
SO
2 -, -NRG 2
SO
2
NRG
3 -, or -SO 2
NRG
2 -, wherein each occurrence of RGI, RG and RG 3 independently inCludes, but is not 5 limited to, hydrogen, halogen, or an optionally substituted aliphatic, heteroaliphatic, alicyclic, heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0034] The term "heteroalicyclic", "heterocycloalkyl" or "heterocyclic", as used herein, 10 refers to compounds which combine the properties of heteroaliphatic and cyclic compounds and include but are not limited to saturated and unsaturated mono- or polycyclic ring systems having 5-16 atoms wherein at least one ring atom is a heteroatom selected from 0, S and N (wherein the nitrogen and sulfur heteroatoms may be optionally be oxidized), wherein the ring systems are optionally substituted with one or more functional groups, as defined herein. In certain 15 embodiments, the term "heterocyclic" refers to a non-aromatic 5-, 6- or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 2 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may 20 optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to an aryl or heteroaryl ring. Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. In certain embodiments, a "substituted heterocycloalkyl or 25 heterocycle" group is utilized and as used herein, refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one or more hydrogen atoms thereon with aliphatic; heteroaliphatic; alicyclic; heterocyclic; aromatic, heteroaromatic; aryl; heteroaryl; alkylaryl; alkyiheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -NO 2 ; -CN; -CF 3 ; -CH 2
CF
3 ; 30 -CHC1 2 ; -CH 2 OH; -CH 2
CH
2 OH; -CH 2
NH
2 ; -CH 2
SO
2
CH
3 ; or -GRG1 wherein G is -0-, -S-, -NRG2-, -C(=0)-, -S(=O)-, -SO 2 -, -C(=0)O-, -C(=O)NRG 2 -, -OC(=0)-, -NRG 2 C(=O)_, ~OC(=O)O-, -OC(=O)NRG 2 -, -NRG 2 C(=O)O-, -NRG2C(=O)NRG2_, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG 2 )-, -C(=NRG 2 )O-, -C(=NRG 2
)NRG
3 -, -OC(=NRG 2 )-, -NRG 2
C(=NRG
3 )_, 12 WO 2009/054952 PCT/US2008/011990
-NRGSO
2 -, -NRG 2
SO
2 NRG-, or -SO 2
NR
2 , wherein each occurrence of RGl, R 2 and RG independently includes, but is not limited to, hydrogen, halogen, or an optionally substituted aliphatic, heteroaliphatic, alicyclic, heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety. Additional examples or generally applicable substituents 5 are illustrated by the specific embodiments shown in the Examples, which are described herein. [0035] Additionally, it will be appreciated that any of the alicyclic or heterocyclic moieties described above and herein may comprise an aryl or heteroaryl moiety fused thereto. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. 10 [0036] In general, the term "aromatic moiety", as used herein, refers to a stable mono- or polycyclic, unsaturated moiety having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted. In certain embodiments, the term "aromatic moiety" refers to a planar ring having p-orbitals perpendicular to the plane of the ring at each ring atom and satisfying the Huckel rule where the number of pi electrons in the ring is (4n+2) wherein n is an 15 integer. A mono- or polycyclic, unsaturated moiety that does not satisfy one or all of these criteria for aromaticity is defined herein as "non-aromatic", and is encompassed by the term "alicyclic". Examples of aromatic moieties include, but are not limited to, phenyl, indanyl, indenyl, naphthyl, phenanthryl and anthracyl. [0037] In general, the term "heteroaromatic moiety", as used herein, refers to stable 20 substituted or unsubstituted unsaturated mono-heterocyclic or polyheterocyclic moieties having preferably 3-14 carbon atoms, comprising at least one ring having p-orbitals perpendicular to the plane of the ring at each ring atom, and satisfying the Huckel rule where the number of pi electrons in the ring is (4n+2) wherein n is an integer. Examples of heteroaromatic moieties include, but are not limited to, pyridyl, quinolinyl, dihydroquinolinyl, isoquinolinyl, 25 quinazolinyl, dihydroquinazolyl, and tetrahydroquinazolyl. [0038] It will also be appreciated that aromatic and heteroaromatic moieties, as defined herein, may be attached via an aliphatic (e.g., alkyl) or heteroaliphatic (e.g., heteroalkyl) moiety and thus also include moieties such as -(aliphatic)aromatic, -(heteroaliphatic)aromatic, -(aliphatic)heteroaromatic, -(heteroaliphatic)heteroaromatic, -(alkyl)aromatic, 30 -(heteroalkyl)aromatic, -(alkyl)heteroaromatic, and -(heteroalkyl)heteroaromatic moieties. Thus, as used herein, the phrases "aromatic or heteroaromatic moieties" and "aromatic, heteroaromatic, -(alkyl)aromatic, -(heteroalkyl)aromatic, -(heteroalkyl)heteroaromatic, and -(heteroalkyl)heteroaromatic" are interchangeable. In some instances corresponding moieties 13 WO 2009/054952 PCT/US2008/011990 may be referred to synonymously as aralkyl, heteroaralkyl and the like. Substituents include, but are not limited to, any of the previously mentioned substituents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. 5 [0039] In general, the term "aryl" refers to aromatic moieties, as described above, excluding those attached via an aliphatic (e.g., alkyl) or heteroaliphatic (e.g., heteroalkyl) moiety. In certain embodiments of the present invention, "aryl" refers to a mono- or bicyclic carbocyclic ring system having one or two rings satisfying the Huckel rule for aromaticity, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. 10 [0040] Similarly, the term "heteroaryl" refers to heteroaromatic moieties, as described above, excluding those attached via an aliphatic (e.g., alkyl) or heteroaliphatic (e.g., heteroalkyl) moiety. In certain embodiments of the present invention, the term "heteroaryl", as used herein, refers to a cyclic unsaturated radical having from about five to about ten ring atoms of which one ring atom is selected from S, 0 and N; zero, one or two ring atoms are additional heteroatoms 15 independently selected from S, 0 and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like. [0041] As defined herein, "aryl" and "heteroaryl" groups (including bicyclic aryl groups) can 20 be unsubstituted or substituted, wherein substitution includes replacement of one or more of the hydrogen atoms thereon independently with any of the previously mentioned substitutents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. For example, aryl and heteroaryl groups (including bicyclic aryl groups) can be unsubstituted or substituted, wherein substitution includes 25 replacement of one or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; alicyclic; heterocyclic; aromatic, heteroaromatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -NO 2 ; -CN; -CF 3 ; -CH 2
CF
3 ; -CHC1 2 ; -CH 2 OH; -CH 2
CH
2 0H; -CH 2
NH
2 ; -CH 2
SO
2
CH
3 ; or 30 -GRe wherein G is -0-, -S-, -NRG 2 -, -C(=O)-, -S(=0)-, -SO 2 -, -C(=0)O-, -C(=O)NRG2_, -OC(=O)-, -NRG 2 C(=O)-, -OC(=O)O-, -OC(=O)NRG 2 -, -NRG 2 C(=O)O-, -NRG 2
C(=O)NRG
2 _, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG 2 )-, -C(=NRG 2 )O-, -C(=NRG2)NRG3_,
-OC(=NR
2 )-, -NRG 2
C(=NRG
3 )-, -NR 2
SO
2 -, -NRG 2
SO
2
NRG
3 -, or -SO 2
NRG
2 -, wherein each 14 WO 2009/054952 PCT/US2008/011990 occurrence of RG, RG' and RG 3 independently includes, but is not limited to, hydrogen, halogen, or an optionally substituted aliphatic, heteroaliphatic, alicyclic, heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety. Additionally, it will be appreciated, that any two adjacent groups taken together may represent a 4, 5, 6, or 7-membered 5 substituted or unsubstituted alicyclic or heterocyclic moiety. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein. [0042] The term "alkoxy" or "alkyloxy", as used herein refers to a saturated (i.e., 0-alkyl) or unsaturated (i.e., 0-alkenyl and O-alkynyl) group attached to the parent molecular moiety 10 through an oxygen atom. In certain embodiments, the alkyl group contains 1-20; 2-20; 3-20; 4-20; 5-20; 6-20; 7-20 or 8-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10; 2-10; 3-10; 4-10; 5-10; 6-10; 7-10 or 8-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8; 2-8; 3-8; 4-8; 5-8; 6-20 or 7-8 aliphatic carbon atoms. In still other embodiments, the alkyl 15 group contains 1-6; 2-6; 3-6; 4-6 or 5-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4; 2-4 or 3-4 aliphatic carbon atoms. Examples of alkoxy, include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, i-butoxy, sec-butoxy, tert butoxy, neopentoxy, n-hexoxy and the like. [0043] The term "thioalkyl" as used herein refers to a saturated (i.e., S-alkyl) or unsaturated 20 (i.e., S-alkenyl and S-alkynyl) group attached to the parent molecular moiety through a sulfur atom. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon 25 atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms. Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, and the like. [0044] The term "alkylamino" refers to a group having the structure -NHR'wherein R' is aliphatic or alicyclic, as defined herein. The term "aminoalkyl" refers to a group having the 30 structure NH 2 R'-, wherein R' is aliphatic or alicyclic, as defined herein. In certain embodiments, the aliphatic or alicyclic group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the aliphatic or alicyclic group contains 1-10 aliphatic carbon atoms. In still other embodiments, the aliphatic or alicyclic group contains 1-6 aliphatic carbon atoms. In yet other 15 WO 2009/054952 PCT/US2008/011990 embodiments, the aliphatic or alicyclic group contains 1-4 aliphatic carbon atoms. In yet other embodiments, R' is an alkyl, alkenyl, or alkynyl group containing 1-8 aliphatic carbon atoms. Examples of alkylamino include, but are not limited to, methylamino, ethylamino, iso propylamino and the like. 5 [0045] Some examples of substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; alicyclic; heteroaliphatic; heterocyclic; aromatic; heteroaromatic; aryl; heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl; heteroalkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2
CF
3 ; -CHC1 2 ; 10 -CH 2 OH; -CH 2
CH
2 OH; -CH 2
NH
2 ; -CH 2
SO
2
CH
3 ; -C(=O)Rx; -CO 2 (R,); -C(=O)N(Rx) 2 ; -OC(=0)R.; -OCO2Rx; -OC(=O)N(Rx)2; -N(Rx,)2; -ORx; -SRx; -S(O)Rx; -S(O)2Rx.; -NRx(CO)Rx; -N(Rx)CO 2 Rx; -N(Rx)S(O) 2 Rx; -N(Rx)C(=O)N(Rx) 2 ; -S(0) 2 N(Rx) 2 ; wherein each occurrence of Rx independently includes, but is not limited to, aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or heteroalkylheteroaryl, wherein any 15 of the aliphatic, alicyclic, heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, saturated or unsaturated, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are 20 described herein. [0046] The terms "halo" and "halogen" as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine. [0047] The term "haloalkyl" denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, 25 bromoethyl, trifluoromethyl, and the like. [0048] The term "amino", as used herein, refers to a primary (-NH 2 ), secondary (-NHR,), tertiary (-NRxRy) or quaternary (-N*RxRyRz) amine, where Rx, Ry and Rz are independently an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety, as defined herein. Examples of amino groups include, but are not limited to, methylamino, dimethylamino, 30 ethylamino, diethylamino, diethylaminocarbonyl, methylethylamino, iso-propylamino, piperidino, trimethylamino, and propylamino. 16 WO 2009/054952 PCT/US2008/011990 [0049] The term "acyl", as used herein, refers to a group having the general formula C(=O)R, where R is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety, as defined herein. [0050] The term "C 2
.
6 alkenylene", as used herein, refers to a substituted or unsubstituted, 5 linear or branched unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to six carbon atoms, having a free valence "-" at both ends of the radical, and wherein the unsaturation is present only as double bonds and wherein a double bond can exist between the first carbon of the chain and the rest of the molecule. [0051] As used herein, the terms "aliphatic", "heteroaliphatic", "alkyl", "alkenyl", "alkynyl", 10 "heteroalkyl", "heteroalkenyl", "heteroalkynyl", and the like encompass substituted and unsubstituted, saturated and unsaturated, and linear and branched groups. Similarly, the terms "alicyclic", "heterocyclic", "heterocycloalkyl", "heterocycle" and the like encompass substituted and unsubstituted, and saturated and unsaturated groups. Additionally, the terms "cycloalkyl", "cycloalkenyl", "cycloalkynyl", "heterocycloalkyl", "heterocycloalkenyl", "heterocycloalkynyl", 15 "aromatic", "heteroaromatic", "aryl", "heteroaryl" and the like encompass both substituted and unsubstituted groups. [0052] The phrase, "pharmaceutically acceptable derivative", as used herein, denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or 20 indirectly) a compound as otherwise described herein, or a metabolite or residue thereof. Pharmaceutically acceptable derivatives thus include among others pro-drugs. A pro-drug is a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety, which is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species. An example of a pro-drug is an ester, which is 25 cleaved in vivo to yield a compound of interest. Another example is an N-methyl derivative of a compound, which is susceptible to oxidative metabolism resulting in N-demethylation. Pro drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. Certain exemplary pharmaceutical compositions and pharmaceutically acceptable derivatives 30 will be discussed in more detail herein below. [0053] The term "tautomerization" refers to the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See, Jerry March, Advanced Organic Chemistry: Reactions, 17 WO 2009/054952 PCT/US2008/011990 Mechanisms and Structures, Fourth Edition, John Wiley & Sons, pages 69-74 (1992). The term "tautomer" as used herein, refers to the compounds produced by the proton shift. [00541 By the term "protecting group", as used herein, it is meant that a particular functional moiety, e.g., 0, S, or N, is temporarily blocked so that a reaction can be carried out selectively at 5 another reactive site in a multifunctional compound. In preferred embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic 10 centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen and carbon protecting groups may be utilized. For example, in certain embodiments, as detailed herein, certain exemplary oxygen protecting groups are utilized. These oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM 15 (methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM or MPM (p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilylether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, TBDPS (t-butyldiphenyl silyl ether), to name a few), esters (e.g., formate, acetate, benzoate (Bz), 20 trifluoroacetate, dichloroacetate, to name a few), carbonates, cyclic acetals and ketals. In certain other exemplary embodiments, nitrogen protecting groups are utilized. These nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), to name a few) amides, cyclic imide derivatives, N-alkyl and N-aryl amines, imine derivatives, and enamine derivatives, to name a few. Certain 25 other exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the present invention. Additionally, a variety of protecting groups are described in "Protective Groups in Organic Synthesis" Third Ed. Greene, T.W. and Wuts, P.G., Eds., John 30 Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference. [00551 As used herein, the term "isolated" when applied to the compounds of the present invention, refers to such compounds that are (i) separated from at least some components with 18 WO 2009/054952 PCT/US2008/011990 which they are associated in nature or when they are made and/or (ii) produced, prepared or manufactured by the hand of man. [0056] As used herein the term "biological sample" includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from an animal (e.g., mammal) or 5 extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof; or purified versions thereof. For example, the term "biological sample" refers to any solid or fluid sample obtained from, excreted by or secreted by any living organism, including single-celled microorganisms (such as bacteria and yeasts) and multicellular organisms (such as plants and animals, for instance a vertebrate or a mammal, and in particular a healthy or 10 apparently healthy human subject or a human patient affected by a condition or disease to be diagnosed or investigated). The biological sample can be in any form, including a solid material such as a tissue, cells, a cell pellet, a cell extract, cell homogenates, or cell fractions; or a biopsy, or a biological fluid. The biological fluid may be obtained from any site (e.g. blood, saliva (or a mouth wash containing buccal cells), tears, plasma, serum, urine, bile, seminal fluid, 15 cerebrospinal fluid, amniotic fluid, peritoneal fluid, and pleural fluid, or cells therefrom, aqueous or vitreous humor, or any bodily secretion), a transudate, an exudate (e.g. fluid obtained from an abscess or any other site of infection or inflammation), or fluid obtained from a joint (e.g. a normal joint or a joint affected by disease such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis). The biological sample can be obtained from any organ or tissue (including a 20 biopsy or autopsy specimen) or may comprise cells (whether primary cells or cultured cells) or medium conditioned by any cell, tissue or organ. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. Biological samples also include mixtures of biological molecules including proteins, lipids, carbohydrates and nucleic acids generated by partial or complete fractionation of cell or tissue homogenates. Although the 25 sample is preferably taken from a human subject, biological samples may be from any animal, plant, bacteria, virus, yeast, etc. The term animal, as used herein, refers to humans as well as non-human animals, at any stage of development, including, for example, mammals, birds, reptiles, amphibians, fish, worms and single cells. Cell cultures and live tissue samples are considered to be pluralities of animals. In certain exemplary embodiments, the non-human 30 animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). An animal may be a transgenic animal or a human clone. If desired, the biological sample may be subjected to preliminary processing, including preliminary separation techniques. 19 WO 2009/054952 PCT/US2008/011990 DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION [0057] Ischemia-reperfusion injury resulting in acute tubular necrosis is a major contributing factor for kidney dysfunction, and can be caused by extra renal surgery, such as the repair of a 5 thoracoabdominal aneurysm or cardio-pulmonary bypass, leading to hypovolemic shock to the kidney, and in the setting of kidney transplantation. In fact, in complex thoracoabdominal surgery, associated renal dysfunction is an independent predictor of operative mortality, increasing it approximately 3 fold. In the United States, in November 2006 there are 69,000 patients on the waiting list for a kidney transplant, and of the 9,270 donor kidneys recovered as 10 reported through August of this year, 4,865 from deceased donors (Organ Procurement and Transplantation Network, OPTN). The observation that the success of cadaver donors transplantation is consistently worse than living unrelated or one haplotype-matched living related donors must be based on nonspecific, antigen-independent variables, with one such factor, ischemia-reperfusion injury may be the most important. In fact, about 20-30 % of the 15 cadaver-donor kidneys suffer from delayed graft function, due to acute tubular necrosis. As more organs are removed from "marginal" or "extended" donors (i.e. aged >60 years, with hypertension, acute tubular necrosis etc.) as there has been an upward trend in the use of cadaver-donor kidneys in the past two years (OPTN), these rates of delayed renal function and ultimately graft failure may increase due to antigen-independent factors associated with 20 ischemia-reperfusion injury. Long-term graft behavior may also be influenced by this initial ischemia -reperfusion injury leading to poor graft function as reported in patients 1 and 5 years post-transplant. Also, the duration of storage of these cadaver-donor kidneys appears to contribute to the severity of this initial ischemia-reperfusion injury, as reported by Salahudeen and colleagues in their retrospective analysis of 6465 kidney transplant patients in which that 25 prolonged cold ischemia was shown to be a significant predictor of long-term graft loss. [0058] The pathophysiology of ischemia-reperfusion injury of the kidney is manifested by two major events: a significant reduction in glomerular filtration rate by as much as 95%, and the reduction of renal blood flow to 50% of normal. Though the degree of damage will increase with the duration of cold or warm ischemia, microscopic evaluation of the outer medulla after 45-60 30 minutes of warm ischemia reveals extensive necrosis of the third (S3) segment of the proximal tubule with associated interstitial edema, tubular dilation, tubular flattening and luminal obstructions. The underlying changes to the metabolism of the oxygen-deprived tubule cells through this process of ischemia and reperfusion are as follows; during the period of ischemia, 20 WO 2009/054952 PCT/US2008/011990 which rapidly damages metabolically active cells, oxidative metabolism is greatly reduced while anaerobic metabolism continues. The disruption of mitochondrial oxidative phosphorylation leads to a rapid decrease in cellular ATP and NAD/NADH levels, and ATP is rapidly dephosphorylated to adenosine monophosphate, which in turn is degraded to hypoxanthine. ATP 5 depletion causes the degradation of ATP-dependent ion channels leading to the passive shift of ions: K+ and Mg" diffuse out of the cells while Na*, Ca" and H 2 0 flow down the concentration gradient into the cell, causing cell swelling and the conversion of xanthine dehydrogenase to (HDH) to xanthine oxidase (XO) by a calcium dependent protease. In addition, anaerobic metabolism during ischemia also induces free Fe" cellular levels, Fe" being an important 10 catalyst in the reactions forming free radicals during reperfusion. During reperfusion, XO and Fe" catalyze the formation of the reactive oxygen species (ROS) 02.~, H 2 0 2 and OH.~. Also, the kidney vascular endothelium is a major source of nitric oxide (NO), and following reperfusion this endothelial cell derived NO has been shown to react with 02.: to form the potent oxidant ONOO- (peroxynitrite). These toxic, reactive oxygen molecules cause lipid peroxidation, DNA 15 damage, protein denaturation, and altered membrane transport proteins and necrotic cell death. [0059] The evidence for the presence of, and the direct role of, ROS in ischemia-reperfusion injury in the kidney are the results in animal studies demonstrating Ischemia-reperfusion increased production of lipid peroxidation, which appeared within minutes of reperfusion. Also, Green and colleagues demonstrated that the lipid peroxidation did not occur during prolonged 20 hypothermic kidney storage in a rabbit transplantation model, only appearing with reperfusion. Finally introduction of the superoxide scavenger, superoxide dismutase (SOD) via adenovirus mediated expression in recipient rats, and of a randomized clinical study of intravenous administration of recombinant SOD at the time of transplantation of cadaveric kidney demonstrated beneficial effect. In the rat study, ischemia-reperfusion injury was lessened by 25 SOD transgene expression as measured by lessening of tubular injury, decreased infiltration of leukocytes and improved glomerular filtration rate. In the clinical study, although not shown to cause an immediate improvement in renal function, SOD administration was associated with improved long-term graft survival. [0060] As mentioned above, ROS have been shown to mediate over-activation of PARP-1, 30 which has been demonstrated to cause critical ATP depletion leading to cell necrosis, as the toxic effects can be substantially ameliorated by either: PARP-1 inhibitors in the cell lineages; macrophages, aortic smooth muscle, neuronal and endothelial, or absence of active PARP-1 in PARP-1-/- deficient fibroblasts. 21 WO 2009/054952 PCT/US2008/011990 [00611 Human malignant gliomas (astrocytomas and glioblastomas) are the most commonly diagnosed primary CNS tumors, with 20,500 new cases and 12,740 deaths estimated by National Cancer Institute for 2007. Despite decades of advances in neurosurgery, radiation therapy, and novel chemotherapeutic regimens, the mean survival time from diagnosis with glioma has been 5 extended only by months with only 5% of patients surviving five years after diagnosis 1-4. This continued high death rate stresses the need for novel therapeutics that could significantly prolong the patient's life and quality of life. In the past few years we have seen FDA approval of several of these novel therapeutics, which target key proteins, which promote tumor growth, angiogenesis, and metastasis; such as GLEEVEC@, AVASTIN@, HERCEPTIN@ and 10 TARCEVA@, demonstrating significant therapeutic benefit in a variety of cancers. Unfortunately, malignant gliomas have proven refractory to significant therapeutic benefit by such molecular-targeted agents, still leaving us with the critical need for better therapies. Componds embodied herein can be used in combination with and to improve the efficacy of radiation therapy and chemotherapeutic regimens already used for glioma as well as with other 15 cancers. [0062] Familial breast and ovarian cancers, which account for 5-10% of these cancers, are commonly caused by the inherited defect in one of the BRCA1 or BRCA2 alleles. During life the normal, functional BRCA1 or BRCA2 alleles can be lost in some cells, thus initiating the development of a tumor. The tumors that developed were BRCA1 or BRCA2 deficient while 20 remaining somatic cells had functional BRCA proteins. As described above, such tumor cells would be expected to be extremely sensitive to PARP-1 inhibition and this has been confirmed recently. Two independent groups demonstrated specific killing of BRCA deficient cells and inhibition of tumor xenograft growth by pharmacological inhibition of PARP-1 alone with no requirement to combine with chemotherapy. 25 [0063] The foregoing target diseases and conditions are merely illustrative of the plethora of diseases and conditions for which the compounds embodied herein are useful therapeutically or prophylactically, as enumerated elsewhere herein by way of non-limiting example only. General Description of Compounds of the Invention [0064] In certain embodiments, compounds of the invention include compounds of the 30 general Formula (I) as defined below: 22 WO 2009/054952 PCT/US2008/011990
R
2 R'N
R
3 -N N 0 -- / N-NH or a pharmaceutically acceptable salt thereof; wherein R' and R 2 are independently H or COW; 5 R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and
R
4 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety. [0065] Examples of compounds of formula (I) are included in formulas II-IV below. 10 [0066] In other embodiments, compounds of the invention include compounds of the general formula (II) as further defined below: HN
R
3 -N N O NH0 N-NH II or a pharmaceutically acceptable salt thereof; 15 wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and wherein R is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety. [0067] In certain embodiments, R 3 is a lower alkyl group. In certain embodiments R 3 is a 20 methyl group. In certain other embodiments R 3 is other than a lower alkyl group. In yet other embodiments, R3 is other than a methyl group. [0068] In other embodiment R 3 is hydrogen, ethyl, 1-methylpiperidine, cyclopropylmethyl or acetic acid. [0069] In certain embodiments, R is an optionally substituted alkyl, cycloalkyl, aryl, 25 heteroaryl and alkyloxycarbonyl moiety. 23 WO 2009/054952 PCT/US2008/011990 [0070] For example, R 4 is an optionally substituted aralkyl group such as benzyl, 4 chlorobenzyl, or 4-nitrobenzyl. In other embodiments R 4 is an optionally substituted aryl group such as phenyl, 3-cyanophenyl, 3-methoxyphenyl, 3,4-methylenedioxyphenyl or 4-nitrophenyl. In other embodiments R4 is an optionally substituted heteroaryl group such as 2-furyl, or an 5 optionally substituted heteroaralkyl group such as (2-thienyl)methyl. [0071] In other embodiments, R 4 is an optionally substituted aliphatic moiety. [0072] In other embodiments, R 4 is an optionally substituted heteroaliphatic or heteroaryl group. Such examples where the first atom is N are described in formula III below. [0073] Non-limiting examples of compounds of Formula II comprise: 10 methyl 2-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenylamino)-2 oxoacetate; 2-(4-chlorophenyl)-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)acetamide; 2-(dimethylamino)-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 15 yl)phenyl)acetamide; 2-chloro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 2-methoxy-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)acetamide; 3-cyano-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)benzamide; 20 3-methoxy-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzamide; 4-fluoro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)benzamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; 25 N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; N-(2-(4-isopropylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 24 WO 2009/054952 PCT/US2008/011990 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)-2-(thiophen-2 yl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)-2 phenylacetamide;n-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)-4 5 nitrobenzamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acrylamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzo[d] [1,3]dioxole-5-carboxamide; 10 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)cyclohexanecarboxamide; N-(2-(4-methylpiperazin- 1-yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)cyclopropanecarboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)furan-2 15 carboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)isobutyramide; N-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)pivalamide; and N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide. [0074] In yet other embodiments of formula (II) above, compounds of the invention include 20 compounds of the general Formula (III) as further defined below:
R
6
R
5 N )=o HN
R
3 -N N O N-NH III or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, 25 heterocyclic, aromatic, heteroaromatic or acyl moiety; and 25 WO 2009/054952 PCT/US2008/011990
R
5 and R6 are each independently an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety; or R 5 and R6 can be joined together to form a ring; or one of R' and R6 is H. [0075] In certain embodiments, R 5 is an optionally substituted alkyl, cycloalkyl, aryl, or acyl 5 moiety. In other embodiments, R 6 is H. In other embodiments, R 3 is H or an alkyl moiety. [0076] In other embodiments, R5 and R6 can be joined together to form a ring, such as but not limited to a pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, dihydroquinolinyl, dihydroquinazolyl, and tetrahydroquinazolyl 10 ring. [0077] Non-limiting examples of compounds of formula III include: N-(2-(4-methylpiperazin- 1-yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenylcarbamoyl)benzamide; 1-(4-fluorophenyl)-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 15 yl)phenyl)urea; 1 -tert-butyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)urea; 1-cyclohexyl-3-(2-(4-methylpiperazin- 1-yl)-5-(4-oxo-3,4-dihydrophthalazin- 1-yl)phenyl)urea; 1-cyclopentyl-3-(2-(4-methylpiperazin- 1-yl)-5-(4-oxo-3,4-dihydrophthalazin- 1-yl)phenyl)urea; 1-ethyl-3-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)urea; and 20 1-methyl-3-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)urea. [0078] In still another embodiment, certain novel inventive compounds have the structure shown in Formula (IV) below:
H
2 N
R
3 -N N - \ 0 IV 25 or a pharmaceutically acceptable salt therof; wherein R3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety. 26 WO 2009/054952 PCT/US2008/011990 [0079] In certain embodiments, R3 is a lower alkyl group. In certain embodiments R3 is a methyl group. In certain other embodments R 3 is other than a lower alkyl group. In yet other embodiments, R 3 is other than a methyl group. [0080] In other embodiments, R 3 is H, optionally substituted alkyl, cycloalkyl, heterocyclic, 5 aryl, or heteroaryl moiety. [0081] In certain embodiments, R 3 is other than an aralkyl group. In another embodiment R 3 is other than a benzyl group. In other embodiments, R 3 is other than a hydroxyalkyl group. In other embodments R 3 is other than a hydroxyethyl group. [0082] Non-limiting examples of R 3 include methyl, ethyl, isopropyl, tert-butyl, 3 10 methoxyphenyl, cyclopropyl, propionitryl, and H. [0083] Non-limiting examples of compounds of Formula IV include: 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 -yl)acetic acid; 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)piperazin-1-yl)propanoic acid; tert-butyl 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 -yl)acetate; 15 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)piperazin-1-yl)propanenitrile; 4-(3-amino-4-(4-((tetrahydrofuran-2-yl)methyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(1 -methylpiperidin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2,5-dimethylphenyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2-(dimethylamino)ethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 20 4-(3-amino-4-(4-(2-aminophenyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2-hydroxyethyl)piperazin- I -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2-methoxyethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3 -amino-4-(4-(3 -hydroxypropyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3 -amino-4-(4-(3 -methoxyphenyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 25 4-(3 -amino-4-(4-(cyclohexylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3 -amino-4-(4-(cyclopropylmethyl)piperazin- I -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(pyridin-3 -ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(pyridin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 27 WO 2009/054952 PCT/US2008/011990 4-(3-amino-4-(4-(pyridin-4-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-tert-butylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-benzylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-cyclopentylpiperazin-l -yl)phenyl)phthalazin- 1 (2H)-one; 5 4-(3-amino-4-(4-cyclopropylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-ethylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one; 4-(3-amino-4-(4-isopropylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-methylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one; and 10 4-(3-amino-4-(4-isonicotinoylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one [0084] Compounds of this invention include those generally set forth above and described specifically herein, and are illustrated in part by the various classes, subgenera and species disclosed herein. [00851 A number of important subclasses of each of the foregoing classes of compounds of 15 formulae (I) - (IV) deserve separate mention; these subclasses include subclasses of the foregoing classes in which: i) each occurrence of R1 and R 2 is independently H or COR 4 ; ii) R1 is hydrogen, R 2 is COR 4 and R 4 is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety; 20 iii) R1 is hydrogen, R 2 is COR 4 and R 4 is an alkyl moiety; iv) R' is hydrogen, R 2 is COR 4 and R 4 is an aryl moiety; v) R1 is hydrogen, R2 is COR and R is a heteroaryl moiety; vi) R is hydrogen, R2 is COR 4 and R 4 is an aralkyl moiety; vii) R' is hydrogen, R 2 is COR 4 and R 4 is methyl or cyclohexyl or 3,4 25 methylenedioxyphenyl or furyl moities; viii) R' is hydrogen, R 2 is COR 4 and R 4 is a heteroalkyl moiety; ix) R' is hydrogen, R 2 is COR 4 and R 4 is a NH-alkyl moiety; x) R' is hydrogen, R2 is COR 4 and R 4 is NH-CH 3 ; 28 WO 2009/054952 PCT/US2008/011990 xi) R' is hydrogen, R 2 is COR 4 and R 4 is NH-CH 2
CH
3 ; xii) R' is hydrogen, R2 is COR 4 and R 4 is NH-tert-butyl; xiii) R' is hydrogen and R2 is hydrogen; xiv) R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, 5 heterocyclic, aromatic, heteroaromatic or acyl moiety; xv) R3 is hydrogen; xvi) R3 is an alkyl moiety; xvii) R3 is an aryl moiety; xviii) R3 is a heteroalkyl moiety; 10 xix) R3 is aheteroaryl moiety; xx) R 3 is an aralkyl moiety; xxi) R3 is a heteroaralkyl moiety; xxii) R3 is a heterocyclic moiety; xxiii) R3 is an alkylheterocyclic moiety; 15 xxiv) R 3 is a lower alkyl moiety; xxv) R 3 is an acyl moiety; xxvi) R 3 is methyl; xxvii) R3 is ethyl, iso-propyl, tert-butyl, cyclopropyl, cyclopentyl, methylcyclopropyl, methylcyclohexyl, propionitrile, propionic acid or acetic acid; 20 xxviii) R3 is hydroxylethyl; xxix) R 3 is benzyl; xxx) R3 is pyridyl; xxxi) R3 is pyridylmethyl; xxxii) R 3 is 1-methylpiperidine; 25 xxxiii) R5 is an alkyl moiety; xxxiv) R 5 is a cycloalkyl moiety; xxxv) R 5 is an aryl moiety; 29 WO 2009/054952 PCT/US2008/011990 xxxvi) R 5 is an acyl moiety; xxxvii) R 6 is H; xxxviii) R' and R 6 can be joined together to form a ring; and/or xxxix) R5 and R6 form a pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, 5 imidazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, dihydroquinolinyl, dihydroquinazolyl, or tetrahydroquinazolyl ring; wherein any of the foregoing is optionally substituted. [0086] Additionally, the present invention provides pharmaceutically acceptable derivatives 10 of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents. [00871 Some of the foregoing compounds can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers. Thus, 15 inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain other embodiments, mixtures of stereoisomers or diastereomers are provided. 20 [00881 Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers. In addition to the above-mentioned compounds per se, this invention also 25 encompasses pharmaceutically acceptable derivatives of these compounds and compositions comprising one or more compounds of the invention and one or more pharmaceutically acceptable excipients or additives. [0089] Compounds of the invention may be prepared by crystallization of compounds of formulas (I) - (IV) under different conditions and may exist as one or a combination of 30 polymorphs of compounds of general formulas (I) - (IV) forming part of this invention. For example, different polymorphs may be identified and/or prepared using different solvents, or 30 WO 2009/054952 PCT/US2008/011990 different mixtures of solvents for recrystallization; by performing crystallizations at different temperatures; or by using various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid 5 probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffractogram and/or other techniques. Thus, the present invention encompasses inventive compounds, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 10 [0090] As discussed above, this invention provides novel compounds with a range of biological properties. Preferred compounds of this invention have biological activities relevant for the treatment of diseases, conditions or disorders where decrease in PARP activity would be beneficial. [0091] Additionally, the present invention provides pharmaceutically acceptable derivatives 15 of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents. Certain compounds of the present invention are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 7 5 th 20 Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described 25 herein, utilize a variety of protecting groups. It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. [0092] It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative 30 includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or a prodrug or other adduct or derivative of a compound of this invention which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. 31 WO 2009/054952 PCT/US2008/011990 [00931 Pharmaceutical Compositions [00941 Accordingly, in another aspect of the present invention, pharmaceutical compositions are provided, which comprise any one or more of the compounds described herein (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), and 5 optionally comprise a pharmaceutically acceptable carrier. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. Alternatively, a compound of this invention may be administered to a patient in need thereof in combination with the administration of one or more other therapeutic agents. For example, additional therapeutic agents for conjoint administration or inclusion in a pharmaceutical 10 composition with a compound of this invention may be an approved agent to treat the same or related indication, or it may be any one of a number of agents undergoing approval in the Food and Drug Administration that ultimately obtain approval for the treatment of any disorder related to PARP activity. It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable 15 derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or a pro-drug or other adduct or derivative of a compound of this invention which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. 20 [0095] In one aspect, the invention is directed to compositions including pharmaceutical compositions comprising at least one compound of Formulas (I) - (IV). [00961 As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the 25 like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds, are well known in the art. For example, S.M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or 30 separately by reacting a free base or free acid function with a suitable reagent, as described generally below. For example, a free base function can be reacted with a suitable acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, e.g. 32 WO 2009/054952 PCT/US2008/011990 sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, 5 maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, 10 heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts 15 include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. [0097] Additionally, as used herein, the term "pharmaceutically acceptable ester" refers to 20 esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include 25 formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. [0098] Furthermore, the term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the issues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable 30 benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood, or N-demethylation of a compound of the invention. A thorough discussion 33 WO 2009/054952 PCT/US2008/011990 is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. 5 [0099] As described above, the pharmaceutical compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical 10 Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical 15 composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and 20 suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and 25 magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. [00100] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and 30 elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in 34 WO 2009/054952 PCT/US2008/011990 particular, cottonseed, groundnut (peanut), corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. 5 [00101] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may 10 be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. [00102] The injectable formulations can be sterilized, for example, by filtration through a 15 bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. [00103] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of 20 a liquid suspension or crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in 25 biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. 30 [001041 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are 35 WO 2009/054952 PCT/US2008/011990 solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound. [00105] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, 5 pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain 10 silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form 15 may also comprise buffering agents. [001061 Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other 20 coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled 25 gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like. [00107] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling 30 coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose and starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids 36 WO 2009/054952 PCT/US2008/011990 such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. 5 Examples of embedding compositions that can be used include polymeric substances and waxes. [00108] The present invention encompasses pharmaceutically acceptable topical formulations of inventive compounds. The term "pharmaceutically acceptable topical formulation", as used herein, means any formulation that is pharmaceutically acceptable for intradermal administration of a compound of the invention by application of the formulation to the epidermis. In certain 10 embodiments of the invention, the topical formulation comprises a carrier system. Pharmaceutically effective carriers include, but are not limited to, solvents (e.g., alcohols, poly alcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (e.g., hypotonic or buffered saline) or any other carrier known in the art for topically administering pharmaceuticals. A more complete listing of art 15 known carriers is provided by reference texts that are standard in the art, for example, Remington's Pharmaceutical Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published by Mack Publishing Company, Easton, Pa., the disclosures of which are incorporated herein by reference in their entireties. In certain other embodiments, the topical formulations of the invention may comprise excipients. Any pharmaceutically acceptable excipient known in the 20 art may be used to prepare the inventive pharmaceutically acceptable topical formulations. Examples of excipients that can be included in the topical formulations of the invention include, but are not limited to, preservatives, antioxidants, moisturizers, emollients, buffering agents, solubilizing agents, other penetration agents, skin protectants, surfactants, and propellants, and/or additional therapeutic agents used in combination to the inventive compound. Suitable 25 preservatives include, but are not limited to, alcohols, quaternary amines, organic acids, parabens, and phenols. Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents like EDTA and citric acid. Suitable moisturizers include, but are not limited to, glycerine, sorbitol, polyethylene glycols, urea, and propylene glycol. Suitable buffering agents 30 for use with the invention include, but are not limited to, citric, hydrochloric, and lactic acid buffers. Suitable solubilizing agents include, but are not limited to, quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates. Suitable skin protectants 37 WO 2009/054952 PCT/US2008/011990 that can be used in the topical formulations of the invention include, but are not limited to, vitamin E oil, allatoin, dimethicone, glycerin, petrolatum, and zinc oxide. [00109] In certain embodiments, the pharmaceutically acceptable topical formulations of the invention comprise at least a compound of the invention and a penetration enhancing agent. The 5 choice of topical formulation will depend or several factors, including the condition to be treated, the physicochemical characteristics of the inventive compound and other excipients present, their stability in the formulation, available manufacturing equipment, and costs constraints. As used herein the term " penetration enhancing agent " means an agent capable of transporting a pharmacologically active compound through the stratum corneum and into the epidermis or 10 dermis, preferably, with little or no systemic absorption. A wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, Percutaneous Penetration Enhancers, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla. (1995), which surveys the use and testing of various skin penetration enhancers, and Buyuktimkin et al., Chemical Means of Transdermal Drug 15 Permeation Enhancement in Transdermal and Topical Drug Delivery Systems, Gosh T. K., Pfister W. R., Yum S. I. (Eds.), Interpharm Press Inc., Buffalo Grove, Ill. (1997). In certain exemplary embodiments, penetration agents for use with the invention include, but are not limited to, triglycerides (e.g., soybean oil), aloe compositions (e.g., aloe-vera gel), ethyl alcohol, isopropyl alcohol, octolyphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, 20 propylene glycol, N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate) and N-methyl pyrrolidone. [00110] In certain embodiments, the compositions may be in the form of ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. In certain exemplary embodiments, formulations of the compositions according to the invention are creams, which 25 may further contain saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl or oleyl alcohols, stearic acid being particularly preferred. Creams of the invention may also contain a non-ionic surfactant, for example, polyoxy-40-stearate. In certain embodiments, the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. 30 Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Formulations for intraocular administration are also included. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage 38 WO 2009/054952 PCT/US2008/011990 forms are made by dissolving or dispensing the compound in the proper medium. As discussed above, penetration enhancing agents can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel. 5 [00111] It will also be appreciated that the compounds and pharmaceutical compositions of the present invention can be formulated and employed in combination therapies, that is, the compounds and pharmaceutical compositions can be formulated with or administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a 10 combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with an anti-inflammatory agent), or they may achieve different effects (e.g., control of any adverse effects). In non-limiting examples, one or 15 more compounds of the invention may be formulated with at least one cytokine, growth factor or other biological, such as an interferon, e.g., alpha interferon, or with at least another small molecule compound. Non-limiting examples of pharmaceutical agents that may be combined therapeutically with compounds of the invention include: antivirals and antifibrotics such as interferon alpha, combination of interferon alpha and ribavirin, Lamivudine, Adefovir dipivoxil 20 and interferon gamma; anticoagulants such as heparin and warfarin; antiplatelets e.g., aspirin, ticlopidine and clopidogrel; other growth factors involved in regeneration, e.g., VEGF and FGF and mimetics of these growth factors ; antiapoptotic agents; and motility and morphogenic agents. [00112] In certain embodiments, the pharmaceutical compositions of the present invention 25 further comprise one or more additional therapeutically active ingredients (e.g., anti inflammatory and/or palliative). For purposes of the invention, the term "Palliative " refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not curative. For example, palliative treatment encompasses painkillers, antinausea medications and anti-sickness drugs. 39 WO 2009/054952 PCT/US2008/011990 3) Clinical Uses, Pharmaceutical Uses and Methods of Treatment Clinical uses of the compounds of the invention As described herein, the invention provides methods for the use of any of the compounds disclosed herein for treating or lessening the severity of a disease, disorder or condition 5 associated with PARP activity, and where inhibition of such activity is beneficial for the treatment, lessening the severity of or preventing the occurrence or relapse thereof. Such diseases, disorders and conditions include, but are not limited to, muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, damaged and/or ischemic organs, transplants or grafts; ischemia/reperfusion injury; stroke, traumatic head injury, 10 spinal cord injury, and other cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; other cardiovascular diseases; diabetes; renal failure; multiple sclerosis; and neurodegenerative diseases such as Parkinsonism and Alzheimer disease. In certain exemplary embodiments, the method is for the treatment of wounds for acceleration of healing; amelioration of ischemia/reperfusion injury in the brain, heart, liver, kidney, or other 15 tissues or organs; normalization of myocardial perfusion as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus. Use of the compound is also provided for prophylaxis or preventing the occurrence of the diseases in subjects, and in particular subjects susceptible to of exhibiting risk factors for, the aforementioned diseases and conditions. 20 [00113] Furthermore, compounds embodied herein are elso useful for the treatment of various dysproliferative diseases including but not limited to dysproliferative diseases such as cancer, as well as inflammatory disease in particular where inflammation, especially chronic inflammation, leads to inappropriate vascularization. Examples of cancers, tumors, malignancies, neoplasms, and other dysproliferative diseases that can be treated according to the invention include 25 leukemias, such as myeloid and lymphocytic leukemias, lymphomas, myeloproliferative diseases, and solid tumors, such as but not limited to sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon 30 carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, 40 WO 2009/054952 PCT/US2008/011990 choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, 5 neuroblastoma, and retinoblastoma. In preferred but non-limiting embodiments, brain tumors, including glioma, and pancreatic cancers are amenable to treatment by the compounds of the present invention. [001141 The invention also provides methods for the use of any of the compounds disclosed herein for use as adjuvant therapy with DNA-damaging chemotherapeutics for treatment of 10 various forms of cancer including but not limited melanoma, breast, ovarian and glioblastoma and in treatment of HIV infection. Use of the compound is also provided for prophylaxis or preventing the occurrence of the diseases in subjects, and in particular subjects susceptible to of exhibiting risk factors for, the aforementioned diseases and conditions. [00115] The invention also provides methods for the use of any of the compounds disclosed 15 herein for use as adjuvant therapy with DNA-damaging chemotherapeutics for treatment of various forms of cancer including but not limited melanoma, breast, ovarian and glioblastoma and in treatment of HIV infection. Use of the compound is also provided for prophylaxis or preventing the occurrence of the diseases in subjects, and in particular subjects susceptible to of exhibiting risk factors for, the aforementioned diseases and conditions. 20 [00116] Examples of inflammatory diseases toward which compounds of the invention have benefit include rheumatoid arthritis, atherosclerosis, and neovascularization in the eye as a consequence of diabetic retinopathy. Compounds embodied herein are also useful for potentiating the activity of compounds for the treatment of the aforementioned diseases, in particular chemotherapeutic agents. 25 [00117] The present invention is also directed to treatment of non-malignant tumors and other disorders involving inappropriate cell or tissue growth by administering a therapeutically effective amount of an agent of the invention. For example, the invention is useful for the treatment of arteriovenous (AV) malformations, particularly in intracranial sites. The invention can also be used to treat psoriasis, a dermatologic condition that is characterized by 30 inflammation and vascular proliferation; benign prostatic hypertrophy, a condition associated with inflammation and possibly vascular proliferation; and cutaneous fungal infections. Treatment of other hyperproliferative disorders is also embraced herein. The agents may also be 41 WO 2009/054952 PCT/US2008/011990 used topically to remove warts, birthmarks, moles, nevi, skin tags, lipomas, angiomas including hemangiomas, and other cutaneous lesions for cosmetic or other purposes. 100118] In another embodiment, a method is provided that comprises the step of administering to a subject suffering from a disease or condition associated with PARP activity an 5 effective amount of a compound of any one of formulas (I) - (IV) or a composition thereof; wherein the compound is characterized by its ability to inhibit PARP activity. In a further embodiment, the disease or condition can be muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, damaged and/or ischemic organs, transplants or grafts; ischemia/reperfusion injury; stroke, traumatic head injury, spinal cord injury, and other 10 cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; other cardiovascular diseases; diabetes; renal failure; multiple sclerosis; and neurodegenerative diseases such as Parkinsonism and Alzheimer disease. In certain exemplary embodiments, the method is for the treatment of wounds for acceleration of healing; amelioration of ischemia/reperfusion injury in the brain, heart, liver, kidney, or other tissues or organs; 15 normalization of myocardial perfusion as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus. In other embodiments the disease or condition is a dysproliferative disease such as cancer. In another embodiment the disease is an inflammatory disease. In another embodiment, the compound inhibits PARP with an in vitro IC 50 of about 1 to about 5 20 micromolar. In another embodiment, the compound inhibits PARP with an in vitro IC 50 of about 0.1 to about 1 micromolar. In another embodiment, the compound inhibits PARP with an in vitro ICso of about 0.001 to about 0.1 micromolar. In another embodiment, the compound inhibits PARP with an in vitro IC 50 of more than about 0.001 micromolar. In another embodiment, the compound inhibits PARP with an in vitro IC 50 of less than about 0.001 micromolar. 25 [00119] Exemplary assays [00120] Efficacy of the compounds of the invention on the aforementioned disorders and diseases or the potential to be of benefit for the prophylaxis or treatment thereof may be demonstrated in various studies, ranging from biochemical effects evaluated in vitro and effects on cells in culture, to in-vivo models of disease, wherein direct clinical manifestations of the 30 disease can be observed and measured, or wherein early structural and/or functional events occur that are established to be involved in the initiation or progression of the disease. The positive effects of the compounds of the invention have been demonstrated in a variety of such assays and models, for a number of diseases and disorders. One skilled in the art can readily determine 42 WO 2009/054952 PCT/US2008/011990 following the guidance described herein that a compound of the invention is an inhibitor of PARP. [00121] As detailed in the exemplification herein, in assays to determine the ability of compounds to inhibit PARP and protect against apoptosis and necrosis among the other 5 beneficial activities thereof, certain inventive compounds exhibited ED 50 values < 50 PM. In certain other embodiments, inventive compounds exhibit ED 50 values < 40 pM. In certain other embodiments, inventive compounds exhibit ED 50 values:5 30 pM. In certain other embodiments, inventive compounds exhibit ED 50 values 5 20 pM. In certain other embodiments, inventive compounds exhibit ED 50 values < 10 jiM. In certain other embodiments, inventive compounds 10 exhibit ED 50 values 5 7.5 pM. In certain embodiments, inventive compounds exhibit ED 50 values 5 5 jiM. In certain other embodiments, inventive compounds exhibit ED 50 values 5 2.5 PM. In certain embodiments, inventive compounds exhibit ED 50 values < 1 PM. In certain other embodiments, inventive compounds exhibit ED 50 values < 750 nM. In certain other embodiments, inventive compounds exhibit ED 50 values < 500 nM. In certain other 15 embodiments, inventive compounds exhibit ED 50 values 5 250 nM. In certain other embodiments, inventive compounds exhibit ED 50 values < 100 nM. In other embodiments, exemplary compounds exhibited ED 50 values 5 75 nM. In other embodiments, exemplary compounds exhibited ED 50 values < 50 nM. In other embodiments, exemplary compounds exhibited ED 50 values 5 40 nM. In other embodiments, exemplary compounds exhibited ED 50 20 values < 30 nM. In other embodiments, exemplary compounds exhibited ED 50 values 5 20 nM. In other embodiments, exemplary compounds exhibited ED 50 values K 10 nM. In other embodiments, exemplary compounds exhibited ED 50 values 5 5 nM. In other embodiments, exemplary compounds exhibited ED 50 values < 1 nM. [00122] Furthermore, in assays to determine the ability of compounds to inhibit PARP, some 25 inventive compounds exhibited IC 50 values > -5 pM. In certain other embodiments, inventive compounds exhibit IC 50 values 5 5 pM. In certain other embodiments, inventive compounds exhibit IC 5 o values : 1 pM. In certain other embodiments, inventive compounds exhibit ICso values 5 0.3 pM. In certain other embodiments, inventive compounds exhibit IC 50 values 5 0.1 pM. In certain other embodiments, inventive compounds exhibit IC 5 o values 5 0.03 PM. In 30 certain embodiments, inventive compounds exhibit IC 50 values 5 0.01 PM. In certain other embodiments, inventive compounds exhibit IC 50 values 5 0.003 PM. In certain embodiments, inventive compounds exhibit IC 50 values 5 0.001 pM. 43 WO 2009/054952 PCT/US2008/011990 1001231 Pharmaceutical Uses and Methods of Treatment [00124] Methods are provided herein for the treatment any disorder wherein inhibition of PARP activity is desirable, comprising administering a therapeutically effective amount of a compound of the invention as described herein, to a subject in need thereof. In certain 5 embodiments, a method for the treatment disorders related to these activities is provided comprising administering a therapeutically effective amount of an inventive compound, or a pharmaceutical composition comprising an inventive compound to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result. [001251 In certain embodiments, the method involves the administration of a therapeutically 10 effective amount of the compound or a pharmaceutically acceptable derivative thereof to a subject (including, but not limited to a human or animal) in need of it. Subjects for which the benefits of the compounds of the invention are intended for administration include, in addition to humans, livestock, domesticated, zoo and companion animals. [001261 As discussed above this invention provides novel compounds that have the beneficial 15 activities descreibed herein. In certain embodiments, the inventive compounds are useful for the treatment of renal ischemia and ischemia of other organs. In other embodiments, compounds embodied herein are useful for the treatment of cancer and other dysproliferative diseases and disorders. [001271 It will be appreciated that the compounds and compositions, according to the method 20 of the present invention, may be administered using any amount and any route of administration effective for the treatment of the conditions or diseases in which inhibiting PARP has a therapeutically useful role. Thus, the expression "effective amount" as used herein, refers to a sufficient amount of agent to exhibit this activity and to exhibit a therapeutic effect. The exact amount required will vary from subject to subject, depending on the species, age, and general 25 condition of the subject, the severity of the disease, the particular therapeutic agent, its mode and/or route of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of therapeutic agent appropriate for the patient to be treated. It will be understood, however, that the total daily 30 usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific 44 WO 2009/054952 PCT/US2008/011990 compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known 5 in the medical arts. Furthermore, after formulation with an appropriate pharmaceutically acceptable carrier in a desired dosage, the pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, subcutaneously, intradermally, intra-ocularly, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the 10 severity of the disease or disorder being treated. In certain embodiments, the compounds of the invention may be administered at dosage levels of about 0.001 mg/kg to about 50 mg/kg, preferably from about 0. 1 mg/kg to about 10 mg/kg for parenteral administration, or preferably from about 1 mg/kg to about 50 mg/kg, more preferably from about 10 mg/kg to about 50 mg/kg for oral administration, of subject body weight per day, one or more times a day, to obtain the 15 desired therapeutic effect. It will also be appreciated that dosages smaller than 0.001 mg/kg or greater than 50 mg/kg (for example 50-100 mg/kg) can be administered to a subject. In certain embodiments, compounds are administered orally or parenterally. [00128] Moreover, pharmaceutical compositions comprising one or more compounds of the invention may also contain other compounds or agents for which co-administration with the 20 compound(s) of the invention is therapeutically advantageous. As noted above, embodied compounds potentiate the chemotherapeutic activity of anticancer agents. As many pharmaceutical agents are used in the treatment of the diseases and disorders for which the compounds of the invention are also beneficial, any may be formulated together for administration. Synergistic formulations are also embraced herein, where the combination of at 25 least one compound of the invention and at least one other compounds act more beneficially than when each is given alone. Non-limiting examples of pharmaceutical agents that may be combined therapeutically with compounds of the invention include anticancer agents such as, aldesleukin (PROLEUKIN); alemtuzumab (CAMPATH); alitretinoin (PANRETIN); allopurinol (ZYLOPRIM); altretamine (HEXALEN); amifostine (ETHYOL); anastrozole (ARIMIDEX); 30 arsenic trioxide (TRISENOX); asparaginase (ELSPAR); BCG Live (TICE BCG); bexarotene capsules or gel (TARGRETIN); bleomycin (BLENOXANE); busulfan intravenous (BUSULFEX); busulfan oral (MYLERAN); calusterone (METHOSARB); capecitabine (XELODA); carboplatin (PARAPLATIN); carmustine (BCNU, BICNU); carmustine with 45 WO 2009/054952 PCT/US2008/011990 Polifeprosan 20 Implant (GLIADEL WAFER); celecoxib (CELEBREX); chlorambucil (LEUKERAN); cisplatin (PLATINOL); cladribine (LEUSTATIN, 2-CDA); cyclophosphamide (CYTOXAN, NEOSAR); cytarabine (CYTOSAR-U); cytarabine liposomal (DEPOCYT); dacarbazine (DTIC-DOME); dactinomycin, actinomycin D (COSMEGEN); darbepoetin alfa 5 (ARANESP); daunorubicin liposomal (DANUOXOME); daunorubicin, daunomycin (DAUNORUBICIN or CERUBIDINE); denileukin diftitox (ONTAK); dexrazoxane (ZINECARD); docetaxel (TAXOTERE); doxorubicin (ADRIAMYCIN, RUBEX); doxorubicin liposomal (DOXIL); dromostanolone propionate (DROMOSTANOLONE or MASTERONE INJECTION); Elliott's B solution (ELLIOTT'S B SOLUTION); epirubicin (ELLENCE); Epoetin 10 alfa (EPOGEN); estramustine (EMCYT); etoposide phosphate (ETOPOPHOS); etoposide, VP 16 (VEPESID); exemestane (AROMASIN); filgrastim (NEUPOGEN); floxuridine (intraarterial) (FUDR); fludarabine (FLUDARA); fluorouracil, 5-FU (ADRUCIL); fulvestrant (FASLODEX); gemcitabine (GEMZAR); gemtuzumab ozogamicin (MYLOTARG); goserelin acetate (ZOLADEX); hydroxyurea (HYDREA); ibritumomab Tiuxetan (ZEVALIN); idarubicin 15 (IDAMYCIN); ifosfamide (IFEX); interferon alfa-2a (ROFERON-A or INTRON A); irinotecan (CAMPTOSAR);letrozole (FEMARA); leucovorin (WELLCOVORIN or LEUCOVORIN); levamisole (ERGAMISOL); lomustine, CCNU (CEEBU); meclorethamine, nitrogen mustard (MUSTARGEN); megestrol acetate (MEGACE); melphalan, L-PAM (ALKERAN); mercaptopurine, 6-MP (PURINETHOL); mesna (MESNEX); methotrexate 20 (METHOTREXATE); methoxsalen (UVADEX); mitomycin C (MUTAMYCIN or MITOZYTREX); mitotane (LYSODREN); mitoxantrone (NOVANTRONE); nandrolone phenpropionate (DURABOLIN-50); nofetumomab (VERLUMA); oprelvekin (NEUMEGA); oxaliplatin (ELOXATIN); paclitaxel (PAXENE or TAXOL); pamidronate (AREDIA); pegademase (ADAGEN; PEGADEMASE BOVINE); pegaspargase (ONCASPAR); 25 pegfilgrastim (NEULASTA); pentostatin (NIPENT); pipobroman (VERCYTE); plicamycin, mithramycin (MITHRACIN); porfimer sodium (PHOTOFRIN); procarbazine (MATULANE); quinacrine (ATABRINE); rasburicase (ELITEK); rituximab (RITUXAN);sargramostim (PROKINE); streptozocin (ZANOSAR); talc (SCLEROSOL); tamoxifen (NOLVADEX); temozolomide (TEMODAR); teniposide, VM-26 (VUMON); testolactone (TESLAC); 30 thioguanine, 6-TG (THIOGUANINE);thiotepa (THIOPLEX); topotecan (HYCAMTIN); toremifene (FARESTON); tositumomab (BEXXAR); trastuzumab (HERCEPTIN); tretinoin, ATRA (VESANOID); uracil mustard (URACIL MUSTARD CAPSULES); valrubicin (VALSTAR); vinblastine (VELBAN); vincristine (ONCOVIN); vinorelbine (NAVELBINE); and zoledronate (ZOMETA). 46 WO 2009/054952 PCT/US2008/011990 TREATMENT KIT [001291 In other embodiments, the present invention relates to a kit for conveniently and effectively carrying out the methods in accordance with the present invention. In general, the pharmaceutical pack or kit comprises one or more containers filled with one or more of the 5 ingredients of the pharmaceutical compositions of the invention. Such kits are especially suited for the delivery of solid oral forms such as tablets or capsules. Such a kit preferably includes a number of unit dosages, and may also include a card having the dosages oriented in the order of their intended use. If desired, a memory aid can be provided, for example in the form of numbers, letters, or other markings or with a calendar insert, designating the days in the 10 treatment schedule in which the dosages can be administered. Alternatively, placebo dosages, or calcium dietary supplements, either in a form similar to or distinct from the dosages of the pharmaceutical compositions, can be included to provide a kit in which a dosage is taken every day. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical products, which 15 notice reflects approval by the agency of manufacture, use or sale for human administration. EQUIVALENTS / [001301 The representative examples that follow are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to 20 those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. It should further be appreciated that the contents of those cited references are incorporated herein by reference to help illustrate the state of the art. [001311 The following examples contain important additional information, exemplification 25 and guidance that can be adapted to the practice of this invention in its various embodiments and the equivalents thereof. EXEMPLIFICATION [00132] The compounds of this invention and their preparation can be understood further by the examples that illustrate some of the processes by which these compounds are prepared or 30 used. It will be appreciated, however, that these examples do not limit the invention. Variations of the invention, now known or further developed, are considered to fall within the scope of the present invention as described herein and as hereinafter claimed. 47 WO 2009/054952 PCT/US2008/011990 1) General Description of Synthetic Methods: [00133] The practitioner has a well-established literature of small molecule chemistry to draw upon, in combination with the information contained herein, for guidance on synthetic strategies, protecting groups, and other materials and methods useful for the synthesis of the compounds of 5 this invention. [001341 The various references cited herein provide helpful background information on preparing compounds similar to the inventive compounds described herein or relevant intermediates, as well as information on formulation, uses, and administration of such compounds which may be of interest. 10 [001351 Moreover, the practitioner is directed to the specific guidance and examples provided in this document relating to various exemplary compounds and intermediates thereof. [00136] The compounds of this invention and their preparation can be understood further by the examples that illustrate some of the processes by which these compounds are prepared or used. It will be appreciated, however, that these examples do not limit the invention. Variations 15 of the invention, now known or further developed, are considered to fall within the scope of the present invention as described herein and as hereinafter claimed. [00137] According to the present invention, any available techniques can be used to make or prepare the inventive compounds or compositions including them. For example, a variety of solution phase synthetic methods such as those discussed in detail below may be used. 20 Alternatively or additionally, the inventive compounds may be prepared using any of a variety combinatorial techniques, parallel synthesis and/or solid phase synthetic methods known in the art. [00138] It will be appreciated as described below, that a variety of inventive compounds can be synthesized according to the methods described herein. The starting materials and reagents 25 used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Company (Milwaukee, WI), Bachem (Torrance, CA), Sigma (St. Louis, MO), or are prepared by methods well known to a person of ordinary skill in the art following procedures described in such references as Fieser and Fieser 1991, "Reagents for Organic Synthesis", vols 1-17, John Wiley and Sons, New York, NY, 1991; Rodd 1989 "Chemistry of 30 Carbon Compounds", vols. 1-5 and supps, Elsevier Science Publishers, 1989; "Organic Reactions", vols 1-40, John Wiley and Sons, New York, NY, 1991; March 2001, "Advanced Organic Chemistry", 5th ed. John Wiley and Sons, New York, NY; and Larock 1990, 48 WO 2009/054952 PCT/US2008/011990 "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 2 nd ed. VCH Publishers. These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to a person of ordinary skill in the art having regard to this 5 disclosure. [00139] The starting materials, intermediates, and compounds of this invention may be isolated and purified using conventional techniques, including filtration, distillation, crystallization, chromatography, and the like. They may be characterized using conventional methods, including physical constants and spectral data. 10 General Reaction Procedures: [00140] Unless mentioned specifically, reaction mixtures were stirred using a magnetically driven stirrer bar. An inert atmosphere refers to either dry argon or dry nitrogen. Reactions were monitored either by thin layer chromatography, by proton nuclear magnetic resonance (NMR) or by high-pressure liquid chromatography (HPLC), of a suitably worked up sample of 15 the reaction mixture. General Work Up Procedures: [00141] Unless mentioned specifically, reaction mixtures were cooled to room temperature or below then quenched, when necessary, with either water or a saturated aqueous solution of ammonium chloride. Desired products were extracted by partitioning between water and a 20 suitable water-immiscible solvent (e.g. ethyl acetate, dichloromethane, diethyl ether). The desired product containing extracts were washed appropriately with water followed by a saturated solution of brine. On occasions where the product containing extract was deemed to contain residual oxidants, the extract was washed with a 10% solution of sodium sulphite in saturated aqueous sodium bicarbonate solution, prior to the aforementioned washing procedure. 25 On occasions where the product containing extract was deemed to contain residual acids, the extract was washed with saturated aqueous sodium bicarbonate solution, prior to the aforementioned washing procedure (except in those cases where the desired product itself had acidic character). On occasions where the product containing extract was deemed to contain residual bases, the extract was washed with 10% aqueous citric acid solution, prior to the 30 aforementioned washing procedure (except in those cases where the desired product itself had basic character). Post washing, the desired product containing extracts were dried over anhydrous magnesium or sodium sulphate, and then filtered. The crude products were then 49 WO 2009/054952 PCT/US2008/011990 isolated by removal of solvent(s) by rotary evaporation under reduced pressure, at an appropriate temperature (generally less than 45*C). General Purification Procedures: [001421 Unless mentioned specifically, chromatographic purification refers to flash column 5 chromatography on silica or preparative TLC on silica, using a single solvent or mixed solvent as eluent. Suitably purified desired product containing elutes were combined and concentrated under reduced pressure at an appropriate temperature (generally less than 45*C) to constant mass. Synthesis of Exemplary Compounds: 10 Example 1 4-[3-Amino-4-(4-methyl-piperazin-1-yl)-phenyl]-2H-phthalazin-1-one [00143] Step 1: 2-(4-Chloro-3-nitro-benzoyl)-benzoic acid methyl ester. To a suspension of 2-(4'-chloro-3'-nitrobenzoyl) benzoic acid (10.0g, 32.7 mmol) in anhydrous methanol (100ml) was added SOC1 2 (4.3g, 36.0 mmol) dropwise at room temperature. The mixture was heated to 15 reflux overnight, cooled to room temperature, and left to stand in a refrigerator. The crystaline product was collected by filtration, washed with cold ethanol, dried in vacuo to afford 2-(4 chloro-3-nitro-benzoyl)-benzoic acid methyl ester as white solid. 'H NMR (DMSO-d6, 500 MHz) 8 8.28 (d, 1H), 8.06 (d, 1H), 7.91 (d, 1H), 7.85 (dd, 1H), 7.82 (dd, 1H), 7.75 (t, 1H), 7.57 (d, 1H), 3.62 (s, 3H). 20 [00144] Step-2: 2-[4-(4-Methyl-piperazin-1-yl)-3-nitro-benzoyll-benzoic acid methyl ester. A mixture of 2-(4-chloro-3-nitro-benzoyl)-benzoic acid methyl ester (7.4g, 23.1 mmol) and 1 methylpiperazine (2.5g, 25.4 mmol) in 100 ml acetonitrile was heated to reflux for 48 hours and then cooled to room temperature. The solvent was removed in vacuo to give 2-[4-(4-methyl piperazin-1-yl)-3-nitro-benzoyl]-benzoic acid methyl ester as golden-yellow solid which was 25 directly used in the next step without further purification. 'H NMR (DMSO-d6, 500 MHz) 6 8.07 (d, lH), 8.03 (d, 1H), 7.8 (m, 1H), 7.78 (m, 1H), 7.71 (t, 1H), 7.49 (d, 1H), 7.44 (d, 1H), 3.62 (s, 3H), 3.48 (b, 2H), 3.4-3.1 (m, 6H), 2.79 (s, 3H). [00145] Step-3: 2-[3-Amino-4-(4-methyl-piperazin-1-yl)-benzoyll-benzoic acid methyl ester. A mixture of 2-[4-(4-methyl-piperazin-1-yl)-3-nitro-benzoyl]-benzoic acid methyl ester (2.0g, 30 5.2 mmol) and Pd/C (5%, 250 mg) in 100 ml of methanol was shaken under H 2 at 50 psi at room temperature for 4 hours and then filtered. The filtrate was concentrated in vacuo to give the crude 50 WO 2009/054952 PCT/US2008/011990 product which was triturated with ether, filtered, and dried in vacuo to afford 2-[3-amino-4-(4 methyl-piperazin-1-yl)-benzoyl]-benzoic acid methyl ester. 'H NMR (DMSO-d6, 500 MHz) 6 7.88 (d, lH), 7.67 (t, LH), 7.63 (t, 1H), 7.42 (d, 1H), 7.48 (d, lH), 6.87 (d, 1H), 6.8 (d, 1H), 5.15 (b, lH), 3.6 (s, lH), 3.5-3.4 (in, 2H), 3.4-3.2 m, 4H), 2.9-3.1 (in, 2H), 2.79 (s, 3H). 5 [00146] Step-4: 4-[3-Amino-4-(4-methyl-piperazin- 1 -yl)-phenyll-2H-phthalazin-1-one. A mixture of 2-[3-amino-4-(4-methyl-piperazin-1-yl)-benzoyl]-benzoic acid methyl ester (1.94g, 5.5 mmol) and 1 ml of hydrazine hydrate in 20 ml of ethanol was heated to reflux for 8 hours, cooled to room temperature, and left to stand in a refrigerator. The crystaline product was collected by filtration, washed with cool ethanol, dried in vacuo to give 4-[3-amino-4-(4-methyl 10 piperazin-1-yl)-phenyl]-2H-phthalazin-1-one as pale yellow solid 'H NMR (DMSO-d6, 500 MHz) 6 8.32 (d, 1H), 7.89 (t, 1H), 7.87 (t, 1H), 7.79 (d, 1H), 7.0 (d, 1H), 6.9 (d, 1H), 6.74 (d, 1H), 4.90 (b, 2H), 3.4 (in, 2H), 2.90 (in, 4H), 2.5 (in, 2H), 2.27 (s, 3H). Example 2 4-(3-Amino-4-(4-ethylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one 15 [00147] Step-1: 2-(4-(4-Ethylpiperazin-1-yl)-3-nitrobenzoyl)benzoic acid. To a solution of 2-(4-chloro-3-nitrobenzoyl)benzoic acid (152.8 mg, 0.5 mmol) in acetonitrile (3 mL) was added 1-ethylpiperazine (228 mg, 2.0 mmol) and the mixture was heated at 80 *C overnight. The reaction was allowed to cool to RT, neutralized with dilute HCl and extracted with 10% methanol in DCM. The DCM extract was washed with brine, dried over anhydrous sodium 20 sulfate and evaporated. The crude product was purified by preparative TLC using 20% methanol in DCM as eluent to afford 2-(4-(4-ethylpiperazin-1-yl)-3-nitrobenzoyl)benzoic acid as yellow solid. MS (ES+): m/z 384.0 (MH*). [00148] Step-2: 2-(3-Amino-4-(4-ethylpiperazin-1-yl)benzoyl)benzoic acid. A mixture of 2 (4-(4-ethylpiperazin-1-yl)-3-nitrobenzoyl)benzoic acid (99 mg, 0.258 mmol), palladium on 25 carbon (50 mg), methanol (2 ml) and ethanol (3 mL) was hydrogenated at 1 atm overnight. The reaction mixture was filtered and the filtrate was evaporated to afford 2-(3-amino-4-(4 ethylpiperazin-1-yl)benzoyl)benzoic acid. MS (ES+): m/z 354.0 (MH*). [00149] Step-3: 4-(3-Amino-4-(4-ethylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one. A mixture of 2-(3-amino-4-(4-ethylpiperazin-1-yl)benzoyl)benzoic acid (61 mg, 0.172 mmol), 30 hydrazine hydrate (0.15 ml) and ethanol (3 ml) was refluxed overnight. The reaction mixture was concentrated and the slurry was filtered, the filter cake was washed with cold ethanol and 51 WO 2009/054952 PCT/US2008/011990 dried under vacuum to afford 4-(3-amino-4-(4-ethylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one as off white powder. MS (ES+): m/z 350.0 (MH*). Example 3 4-(3-Amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one 5 [00150] Step 1: 2-(4-chloro-3-nitrobenzoyl)benzoate. To a slurry of 2-(4-chloro-3 nitrobenzoyl)benzoic acid (1.0 g, 3.27 mmol) in methanol (20 mL) was added conc. sulfuric acid ( 0.3 mL) and the mixture was heated to reflux overnight. Methanol was evaporated, aqueous sodium bicarbonate was added and extracted with DCM. The DCM extract was washed with water, brine, dried over anhydrous sodium sulfate and evaporated to give methyl 2-(4-chloro-3 10 nitrobenzoyl)benzoate as white solid. [00151] Step 2: Methyl 2-(3-nitro-4-(piperazin-1-yl)benzoyl)benzoate. To a solution of methyl 2-(4-chloro-3-nitrobenzoyl)benzoate (160 mg, 0.5 mmol) in acetonitrile (3 mL) was added piperazine (172 mg, 2.0 mmol) and the mixture was heated at 80 *C overnight. The reaction was allowed to cool to RT and extracted with 10% methanol in DCM. The DCM 15 extract was washed with brine, dried over anhydrous sodium sulfate and evaporated. The crude product was purified by preparative TLC using 15% methanol in DCM as eluent to afford methyl 2-(3-nitro-4-(piperazin- 1 -yl)benzoyl)benzoate as yellow solid. [001521 Step 3: Methyl 2-(3-amino-4-(piperazin-1-yl)benzoyl)benzoate. A mixture of methyl 2-(3-nitro-4-(piperazin-1-yl)benzoyl)benzoate (100 mg, 0.26 mmol), palladium on carbon (50 20 mg), methanol (2 ml) and ethanol (3 mL) was hydrogenated at 1 atm overnight. The reaction mixture was filtered and the filtrate was evaporated to afford methyl 2-(3-amino-4-(piperazin-1 yl)benzoyl)benzoate. MS (ES+): m/z 340.0 (MH*). [001531 Step 4: 4-(3-Amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one. A mixture of methyl 2-(3-amino-4-(piperazin- 1 -yl)benzoyl)benzoate (40 mg, 0.11 mmol), hydrazine hydrate 25 (0.15 ml) and ethanol (3 ml) was refluxed overnight. The reaction mixture was concentrated and the product was purified by preparative TLC using 20% methanol in DCM as eluent to afford to afford 4-(3-amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one-as off white powder. MS (ES+): m/z 322.0 (MH*). 52 WO 2009/054952 PCT/US2008/011990 Example 4 N-[2-(4-Methyl-piperazin-1-yl)-5-(4-oxo-3,4-dihydro-phthalazin-1-yl)-phenyl]-acetamide [001541 To a suspension of 50 mg (0.15 mmol) of 4-(3-amino-4-(4-methylpiperazin-1 yl)phenyl)phthalazin-1(2H)-one in pyridine (4 mL) was added 19 mg (0.19 mmol) of acetic 5 anhydride at RT. The reaction was stirred at RT overnight. The solvent was removed in vacuo. The crude product was purified by preparative TLC using 10% methanol in DCM as eluent to afford N-[2-(4-methyl-piperazin-1-yl)-5-(4-oxo-3,4-dihydro-phthalazin-1-yl)-phenyl]-acetamide as a white solid. MS (ES+): m/z 378.1 (MH*). Example 5 10 N-(2-(4-Methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1 yl)phenyl)benzo[d] [1,31dioxole-5-carboxamide [00155] To a suspension of 100 mg (0.30 mmol) of 4-(3-amino-4-(4-methylpiperazin-1 yl)phenyl)phthalazin-1(2H)-one in THF (10 mL) was added 182 mg (1.80 mmol) of Et 3 N followed by 221 mg (1.20 mmol) of benzo[d][1,3]dioxole-5-carbonyl chloride at RT. The 15 reaction was stirred at RT overnight. The solvent was removed in vacuo, and to the residue was added water and sat. aq. NaHCO 3 . The precipitate was collected by filtration, washed with water and hexane. The crude product was purified by preparative TLC using 10% methanol in DCM as eluent to afford N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzo[d][1,3]dioxole-5-carboxamide as a white solid. MS (ES+): m/z 484.1 (MH*). 20 Example 6 1-methyl-3-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)urea [00156] A mixture of 4-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one (168 mg, 0.5 mmol) and methylisocyanate (205 mg, 3.6 mmol) in pyridine (4 mL) was heated to 70*C for 6 h. Pyridine was evaporated and the crude product was purified by preparative TLC 25 using 15% methanol in DCM as eluent to afford 1-methyl-3-(2-(4-methylpiperazin-1-yl)-5-(4 oxo-3,4-dihydrophthalazin-1-yl)phenyl)urea. MS (ES+): m/z 393.41 (MH*). [00157] Following analogous procedures as described in the examples above using the appropriate reactants, the following non-limiting examples of compounds were prepared: methyl 2-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1-yl)phenylamino)-2 30 oxoacetate; 53 WO 2009/054952 PCT/US2008/01 1990 2-chloro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 3 -cyano-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)benzamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; 5 N-(2-(4-ethylpiperazin- Il-yl)-5 -(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-ethylpiperazin- Il-yl)-5 -(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; N-(2-(4-isopropylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)-2-(thiophen-2 yl)acetamide; 10 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin 1 yl)phenyl)benzo[d] [1 ,3]dioxole-5-carboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 yl)phenyl)cyclohexanecarboxamide; 15 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)furan-2 carboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)isobutyramide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 20 2-(4-(2-amino-4-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 -yl)acetic acid; 3 -(4-(2-amino-4-(4-oxo-3 ,4-dihydrophthalazin- 1-yl)phenyl)piperazin- 1-yl)propanoic acid; tert-butyl 2-(4-(2-amino-4-(4-oxo-3 ,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 -yl)acetate; 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- I1-yl)propanenitrile; 4-(3 -amino-4-(4-((tetrahydrofiiran-2-yl)methyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 25 4-(3 -amino-4-(4-( 1 -methylpiperidin-4-yl)piperazin- I1-yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2,5 -dimethylphenyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2-(dimethylamino)ethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 54 WO 2009/054952 PCT/US2008/011990 4-(3-amino-4-(4-(2-aminophenyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2-hydroxyethyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2-methoxyethyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(3-hydroxypropyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 5 4-(3-amino-4-(4-(cyclohexylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(cyclopropylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(pyridin-3-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(pyridin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(pyridin-4-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 10 4-(3-amino-4-(4-tert-butylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-benzylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-cyclopentylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-cyclopropylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-ethylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one; 15 4-(3-amino-4-(4-isopropylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-methylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one; and 4-(3-amino-4-(4-isonicotinoylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one. 2) Biological Activity: 20 [00158] 1. In vitro activity of the compounds embodied herein were assayed by the following methods. [00159] Poly (ADP-Ribose) Polymerase - 1 (PARP-1) In Vitro Enzyme Assay: Compounds were screened for inhibitory activity against human PARP- 1 in vitro using the Universal Colorimetric PARP Assay Kit (Trevigen Inc., Gaithersburg, MD) as directed by the supplier. 25 Compounds are assayed in duplicate in 0.5% DMSO final concentration, negative control is no enzyme, while positive control is DMSO vehicle alone. IC 50 determinations are made using Microsoft Excel. For all cell assays, compounds are added to cells in 5%DMSO/PBS for a final 55 WO 2009/054952 PCT/US2008/011990 concentration of 0.5% DMSO. Exemplary dose response curves of some compounds are shown in Figure 1. [00160] ATP Depletion Assay: To determine effect of PARP-1 inhibitors in preserving cellular ATP levels when challenged with human umbilical cord endothelial cells (HUVEC, 5 Cambrex) are preincubated with test PARP- 1 inhibitors for 10 minutes before the addition of 250 uM H 2 0 2 . Cells are then incubated for an additional 1 hour and relative cellular ATP levels measured with CellTiter-Glo Luminescent Cell Viability Assay (Promega Corp.). Results with some compounds embodied herein are shown in Figure 2. [00161] Mitochondrial Respiration Assay: To determine efficacy of PARP-1 inhibitors in 10 preserving mitochondrial respiration when again challenged with H 2 0 2 , HUVEC cells are again preincubated ten minutes with test compounds before the addition of 250 uM H 2 0 2 . One hour later 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyltetrazolium bromide (MTT) is added and incubation continued for an additional 2 hours. At this time the extent of mitochondrial dependent reduction of MTT to formazan within the cells is quantitated by the measurement at 15 OD at 570 nm. [00162] Poly-ADP Ribosylation Assay: To measure the efficacy of compounds for directly inhibiting the PARP dependent ribosylation of target proteins (autoADP-ribosylation being the major product), test compounds are added to the HUVEC cells 10 minutes before the addition of 500 uM H 2 0 2 to induce PARP-l activity. Cells are then incubated for 10 minutes, washed with 20 PBS and lysed. Protein equivalents of resultant cell lysates are then analyzed by SDS-PAGE, blotted to PVDF membranes and probed with the rabbit anti-Poly-(ADP ribose) (PAR) antibody (Calbiochem). Specific antibody reactivity is detected with the addition of goat-anti rabbit HRP conjugated second antibody (Cell Signaling), ECL substrate and developed on film. [00163] HUVEC Cell Assays are conducted as described by C. Szabo, S Cuzzaocrea, B 25 Zingarelli, M O'Connor, and A L Salzman. Endothelial dysfunction in a rat model of endotoxic shock; importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin. Invest. 1997, 100(3); 723-735. [00164] Potentiation of anticancer compound activity in vitro. To determine the cytotoxicity of a compound of the invention towards a tumor cell line or, in the case of the ability to 30 potentiate the anticancer activity of a chemotherapeutic compound, temozolomide can be used. The human non-small cell lung cancer cell line A549 cells are plated at 104 cells/well of 96 well tissue culture plate. If a combination is being tested, twenty-four hours later temozolomide (250 56 WO 2009/054952 PCT/US2008/011990 and 50 micromolar) can be added to the cells alone or plus the addition of 10 micromolar test compound. Cells are then incubated for an additional 72 hours and mitochondrial respiration as a measure of cell viability is assayed by MTT. Inventive compound is able to increase the anti proliferative effect of 250 and 50 micromolar temozolomide. 5 [001651 Compound Cell Toxicity Assay: This test was condicted to determine cell toxicity of compounds by prolonged incubation with HUVEC cells. HUVEC cells are treated with test compounds (again 0.5% DMSO vehicle final concentration) for 46 hours. At this time the mitochondrial respiratory dye MTT is added and incubated for 2 hours. The reduction of MTT to formazan is then quantitated at OD570, and this measure is used as general gauge of cell 10 viability; comprising cell growth and proliferation, apoptosis and necrosis. [001661 The extent of inhibition of PARP activity (IC 50 , micromolar) in the following compounds is provided using the following letter codes: A, >5 micromolar; B, 1.0-5.0 micromolar; C, 0.1-1.0 micromolar; and D, 0.001-0.1 micromolar. N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 C yl)phenyl)acetamide N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)-2-(thiophen-2-yl)acetamide B N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)cyclohexanecarboxamide C N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)furan-2-carboxamide C 3 -cyano-N-(2-(4-methylpiperazin- 1-yl)-5 -(4-oxo-3,4-dihydrophthalazin- C 1 -yl)phenyl)benzamide N-(2-(4-methylpiperazin- 1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1 A yl)phenyl)pivalamide N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 B yl)phenyl)acetamide N-(2-(4-isopropylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 B yl)phenyl)acetamide 57 WO 2009/054952 PCT/US2008/01 1990 N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 - B yl)phenyl)acetamide N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -A yl)phenyl)pivalamide N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 - A yl)phenyl)pivalamide N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 -B yl)phenyl)isobutyramide methyl 2-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 C yl)phenylamino)-2-oxoacetate 2-chloro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin 1 -yl)phenyl)acetamide N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 yl)phenyl)benzo[d] [1 ,3]dioxole-5-carboxamide C N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 yl)phenyl)acetamide. B 1 -cyclohexyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4 dihydrophthalazin- 1 -yl)phenyl)urea C 1 -cyclopentyl-3-(2-(4-methylpiperazin- I1-yl)-5-(4-oxo-3,4 dihydrophthalazin- 1 -yl)phenyl)urea C N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3 ,4-dihydrophthalazin- 1 yl)phenylcarbamoyl)benzamide C I1-ethyl-3 -(2-(4-methylpiperazin- I1-yl)-5-(4-oxo-3,4-dihydrophthalazin 1 -yl)phenyl)ureaB 1 -tert-butyl-3 -(2-(4-methylpiperazin- 1 -yl)-5 -(4-oxo-3 ,4 C dihydrophthalazin- 1 -yl)phenyl)urea 58 WO 2009/054952 PCT/US2008/011990 1 -methyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4 dihydrophthalazin- 1 -yl)phenyl)urea C 1-(4-fluorophenyl)-3 -(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4 C dihydrophthalazin- 1 -yl)phenyl)urea 4-(3-amino-4-(4-methylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one D 4-(3-amino-4-(4-ethylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one D 4-(3-amino-4-(4-isopropylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one D 4-(3-amino-4-(4-tert-butylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one D 4-(3-amino-4-(4-(2-aminophenyl)piperazin-1-yl)phenyl)phthalazin- B 1(2H)-one 4-(3-amino-4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)phthalazin- D 1(2H)-one 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 D yl)propanenitrile 4-(3-amino-4-(piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one D tert-butyl 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin-1 yl)phenyl)piperazin- 1 -yl)acetate C 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 D yl)acetic acid 4-(3-amino-4-(4-(2-(dimethylamino)ethyl)piperazin-1 yl)phenyl)phthalazin- 1 (2H)-one C 4-(3-amino-4-(4-(3-hydroxypropyl)piperazin- 1 -yl)phenyl)phthalazin- D 1(2H)-one 4-(3-amino-4-(4-(1 -methylpiperidin-4-yl)piperazin- 1 D yl)phenyl)phthalazin- 1 (2H)-one 59 WO 2009/054952 PCT/US2008/011990 4-(3-amino-4-(4-((tetrahydrofuran-2-yl)methyl)piperazin- 1 yl)phenyl)phthalazin- 1 (2H)-one C 4-(3 -amino-4-(4-(2-methoxyethyl)piperazin- 1 -yl)phenyl)phthalazin 1(2H)-one 4-(3-amino-4-(4-(pyridin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H) D one 4-(3-amino-4-(4-(cyclohexylmethyl)piperazin- 1 -yl)phenyl)phthalazin- D 1(2H)-one 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 C yl)propanoic acid 4-(3-amino-4-(4-benzylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one C 4-(3-amino-4-(4-(2-hydroxyethyl)piperazin- 1 -yl)phenyl)phthalazin- D 1(2H)-one 4-(3-amino-4-(4-cyclopentylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one D 4-(3-amino-4-(4-cyclopropylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one D 4-(3-amino-4-(4-(pyridin-4-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- D 1(2H)-one 4-(3-amino-4-(4-(pyridin-3-ylmethyl)piperazin-1-yl)phenyl)phthalazin- D 1(2H)-one 4-(3 -amino-4-(4-isonicotinoylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H) one 2. In vivo. [001671 Inhibition of Poly (ADP-ribosylation) as determined by brain immunohistochemistry. In the rat MCAO model, test compound was administered i.v. (5 mg/kg body weight) in a proof 5 of concept study for evidence of brain bioavailability. One hour after onset of occlusion, animals were sacrificed, perfused, and the brains were removed. Frozen section were cut and processed 60 WO 2009/054952 PCT/US2008/011990 by immunohistochemistry for levels of poly (ADP-ribose) in the immediate zone adjacent to the infarct. Representative photographs of the results are shown in Figure 3. Intense cytoplasmic and nuclear staining is readily apparent in the vehicle control samples (Panels A, C) while test compound (panels B, D) significantly decreased the staining of PAR, indicating good brain 5 bioavailability. [001681 Stroke model: inhibition of infarct development when administered at time of occlusion and 4 hours post occlusion. Compound was administered, 5 mg/kg i.v., at time of occlusion, 20 mg/kg i.p immediately after confirmation of occlusion, and at 20 hrs, with sacrifice at 24 hrs. For delayed treatment in the MCAO model, animals were dosed intraperitoneally at 4 10 hours, and 20 hours post-occlusion and sacrificed at 72 hrs. All animals are anesthetized, perfused and processed for TTC staining. Figure 4 demonstrates the relative cerebral infarct areas (dead tissue, white, unstained) of all tissue slices for three animals. In this initial study of the neuroprotective activity of a compound embodied herein, administration at time of occlusion significantly prevented the death of brain tissue (P<0.002). Importantly the compound also 15 significantly decreased infarct size when first administered 4 hours after onset of occlusion (P<0.032). [00169] Myocardial infarction model. The effect of a compound of the invention was examined in a rat model of in vivo myocardial ischemia and reperfusion. Regional myocardial ischemia was initiated by ligating the left anterior descending coronary artery for 45 min (LAD 20 occlusion). After 45 min ischemia, the occlusion was released. In one study, the test compound was administered (5 mg/kg-body weight, iv) before ischemia. In another study, test compound administration (5 mg/kg-body weight, iv) was delayed after ischemia (45 min of LAD occlusion). Following 2 hours reperfusion, animals (n=6/group) were sacrificed and infarct size estimated as a percentage of the area at risk (Evans blue +TTC). Then the above sections were 25 formalin preserved and paraffin embedded sections were evaluated for myocardial apoptosis using the fluorescent Dead End Fluorometric TUNEL System (Promega Corp, Madison, WI) according to manufacturer's instructions. Quantitative analysis was performed using Bioquant Image Analysis Soft ware program (Bioquant, Nashville, TN). [00170] In animals treated prior to ischemia, infarct size was reduced by 58% (p<0.05), and in 30 animals treated after ischemia, by 54% (p<0.05). Measured in the pre-ischemia treatment group, myocardial apoptosis as measured by TUNEL staining, and PAR levels in the non-infarcted ischemic border zone, were correspondingly reduced (p<0.02). 61
Claims (35)
1. A compound having the structure of formula (I) as defined below: R 2 RIN R 3 -N N N -N 5 or a pharmaceutically acceptable salt thereof; wherein R' and R 2 are independently H or COR 4 ; R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and R 4 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, 10 heterocyclic, aromatic, or heteroaromatic moiety.
2. A compound having the structure of formula (II) as defined below: R 4 0 HN N.. 0 R 3 -N N N-NH II 15 or a pharmaceutically acceptable salt thereof; wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and wherein R 4 is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety. 20
3. The compound of claim 2 wherein R 3 is a lower alkyl group.
4. The compound of claim 2 wherein R 4 is an optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or alkyloxycarbonyl moiety. 62 WO 2009/054952 PCT/US2008/011990
5. The compound of claim 2 wherein R 4 is an optionally substituted aliphatic moiety.
6. The compound of claim 2 selected from the group consisting of: 5 methyl 2-(2-(4-methylpiperazin-1-yl)-5-(4-oxo-3,4-dihydrophthalazin-1 yl)phenylamino)-2-oxoacetate; 2-(4-chlorophenyl)-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)acetamide; 2-(dimethylamino)-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 10 yl)phenyl)acetamide; 2-chloro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)acetamide; 2-methoxy-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)acetamide; 15 3-cyano-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzamide; 3-methoxy-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzamide; 4-fluoro-N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 20 yl)phenyl)benzamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-tert-butylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)pivalamide; N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 25 N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-ethylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; N-(2-(4-isopropylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; 63 WO 2009/054952 PCT/US2008/011990 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)-2-(thiophen 2-yl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)-2 phenylacetamide;n-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo- 3 ,4-dihydrophthalazin- 1 5 yl)phenyl)-4-nitrobenzamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acrylamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)benzo[d][1,3]dioxole-5-carboxamide; 10 N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)cyclohexanecarboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)cyclopropanecarboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)furan-2 15 carboxamide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)isobutyramide; N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)pivalamide; and 20 N-(2-(4-acetylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)acetamide.
7. A compound having the structure of formula (III) as defined below: R 6 R'N )=0 HN R 3 -N N O N-N III 25 or a pharmaceutically acceptable salt thereof; 64 WO 2009/054952 PCT/US2008/011990 wherein R3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; and R5 and R6 are each independently an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety; or R5 and R6 are joined 5 together to form a ring; or one of R 5 and R6 is H.
8. The compound of claim 7 wherein R5 is independently an optionally substituted alkyl, cycloalkyl, aryl, or acyl moiety. 10
9. The compound of claim 7 wherein R3 is H or an alkyl moiety.
10. The compound of claim 7 selected from the group consisting of N-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenylcarbamoyl)benzamide; 15 1-(4-fluorophenyl)-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)urea; 1 -tert-butyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)urea; 1 -cyclohexyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 20 yl)phenyl)urea; 1 -cyclopentyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)urea; 1 -ethyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)urea; and 25 1 -methyl-3-(2-(4-methylpiperazin- 1 -yl)-5-(4-oxo-3,4-dihydrophthalazin- 1 yl)phenyl)urea.
11. A compound having a structure of formula (IV) as defined below: 65 WO 2009/054952 PCT/US2008/011990 H 2 N R 3 -N N O NH0 IV or a pharmaceutically acceptable salt thereof; wherein R 3 is hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, 5 heterocyclic, aromatic, heteroaromatic or acyl moiety.
12. The compound of claim 11 wherein R3 is an optionally substituted lower alkyl group.
13. The compound of claim 11 wherein R3 is an optionally substituted cycloalkyl, 10 heterocyclic, aryl, or heteroaryl moiety.
14. The compound of claim 11 selected from the group consisting of: 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)piperazin-1-yl)acetic acid; 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)piperazin-1-yl)propanoic 15 acid; tert-butyl 2-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 yl)acetate; 3-(4-(2-amino-4-(4-oxo-3,4-dihydrophthalazin- 1 -yl)phenyl)piperazin- 1 -yl)propanenitrile; 4-(3-amino-4-(4-((tetrahydrofuran-2-yl)methyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H) 20 one; 4-(3-amino-4-(4-(1 -methylpiperidin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2,5-dimethylphenyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(2-(dimethylamino)ethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2-aminophenyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 25 4-(3-amino-4-(4-(2-hydroxyethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(2-methoxyethyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 66 WO 2009/054952 PCT/US2008/011990 4-(3-amino-4-(4-(3-hydroxypropyl)piperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-(3-methoxyphenyl)piperazin-1 -yl)phenyl)phthalazin-1(2H)-one; 4-(3-amino-4-(4-(cyclohexylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(cyclopropylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 5 4-(3-amino-4-(4-(pyridin-3-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(pyridin-4-yl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-(pyridin-4-ylmethyl)piperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-tert-butylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-benzylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 10 4-(3-amino-4-(4-cyclopentylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-cyclopropylpiperazin- 1 -yl)phenyl)phthalazin- 1 (2H)-one; 4-(3-amino-4-(4-ethylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-isopropylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 4-(3-amino-4-(4-methylpiperazin- 1 -yl)phenyl)phthalazin- 1(2H)-one; 15 4-(3-amino-4-(piperazin-1-yl)phenyl)phthalazin-1(2H)-one; and 4-(3-amino-4-(4-isonicotinoylpiperazin-1-yl)phenyl)phthalazin-1(2H)-one.
15. A pharmaceutical composition comprising a compound of any one of claims 1-14 and a pharmaceutically acceptable carrier, excipient or diluent. 20
16. A method for inhibiting PARP activity in a patient or a biological sample, whch method comprises administering to the patient or exposing the biological sample to an effective amount of a compound of any one of claims 1-14 or a pharmaceutical composition thereof. 25
17. A method of treating or lessening the severity of a disease, disorder or condition in which inhibition of PARP activity is beneficial therefor, which method comprises administering to a patient in need thereof an effective amount of a compound of any one of claims 1-14 or a pharmaceutical composition thereof. 67 WO 2009/054952 PCT/US2008/011990
18. The method of claim 17 wherein the disease, disorder or condition is selected from the group consisting of muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, damaged and/or ischemic organs, transplants or grafts; 5 ischemia/reperfusion injury; stroke, traumatic head injury, spinal cord injury, cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; cardiovascular diseases; diabetes; renal failure; multiple sclerosis; neurodegenerative disease; Parkinsonism; Alzheimer disease; acceleration of wound healing; amelioration of ischemia/reperfusion injury in the brain, heart, liver, kidney, or other tissues or organs; normalization of myocardial perfusion 10 as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus.
19. The method of claim 17 wherein the disease is a dysproliferative disease. 15
20. The method of claim 19 wherein the dysproliferative disease is cancer or an inflammatory disease.
21. The method of claim 20 wherein the inflammatory disease is rheumatoid arthritis, atherosclerosis, and neovascularization in the eye as a consequence of diabetic retinopathy. 20
22. The method of any one of claims 19-21 wherein the patient is also treated with a chemotherapeutic agent other than a compound of formula (I) - (IV) herein.
23. A method comprising the step of administering to a subject suffering from a disease or 25 condition associated with PARP activity an effective amount of a compound of any one of formulas (I) - (IV) or a composition thereof; wherein the compound is characterized by its ability to inhibit PARP activity.
24. The method of claim 23 wherein the disease, disorder or condition is selected from the 30 group consisting of muscular dystrophy, hepatic ischemia-reperfusion injury, cerebral infarction, 68 WO 2009/054952 PCT/US2008/011990 ischemic heart disease, damaged and/or ischemic organs, transplants or grafts; ischemia/reperfusion injury; stroke, traumatic head injury, spinal cord injury, cerebrovascular diseases; myocardial ischemia; atherosclerosis; peripheral vascular disease; cardiovascular diseases; diabetes; renal failure; multiple sclerosis; neurodegenerative disease; Parkinsonism; 5 Alzheimer disease; acceleration of wound healing; amelioration of ischemia/reperfusion injury in the brain, heart, liver, kidney, or other tissues or organs; normalization of myocardial perfusion as a consequence of chronic cardiac ischemia or myocardial infarction; renal failure secondary to chronic diabetes and/or hypertension; and/or diabetes mellitus. 10
25. The method of claim 23 wherein the disease or condition is a dysproliferative disease.
26. The method of claim 25 wherein the dysproliferative disease is cancer.
27. The method of claim 25 wherein the dysproliferative disease is an inflammatory disease. 15
28. The method of any one of claims 25-27 wherein the subject is also treated with a chemotherapeutic agent other than a compound of formula (I) - (IV) herein.
29. The method of claim 23 wherein the compound inhibits PARP with an in vitro ICso of 20 less than about 5 micromolar.
30. The method of claim 29 wherein the compound inhibits PARP with an in vitro ICso of less than about 1 micromolar. 25
31. The method of claim 30 wherein the compound inhibits PARP with an in vitro IC 50 of less than about 0.3 micromolar.
32. The method of claim 31 wherein the compound inhibits PARP with an in vitro IC 50 of less than about 0.1 micromolar. 69 WO 2009/054952 PCT/US2008/011990
33. The method of claim 32 wherein the compound inhibits PARP with an in vitro IC 50 of less than about 0.03 micromolar. 5
34. The method of claim 33 wherein the compound inhibits PARP with an in vitro IC 50 of less than about 0.01 micromolar.
35. The method of claim 34 wherein the compound inhibits PARP with an in vitro IC 50 of less than about 0.003 micromolar. 10 15 70
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99991107P | 2007-10-22 | 2007-10-22 | |
US60/999,911 | 2007-10-22 | ||
PCT/US2008/011990 WO2009054952A2 (en) | 2007-10-22 | 2008-10-22 | Small molecule inhibitors of parp activity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2008317417A1 true AU2008317417A1 (en) | 2009-04-30 |
Family
ID=40580286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008317417A Abandoned AU2008317417A1 (en) | 2007-10-22 | 2008-10-22 | Small molecule inhibitors of PARP activity |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2214667A2 (en) |
AU (1) | AU2008317417A1 (en) |
IL (1) | IL205299A0 (en) |
WO (1) | WO2009054952A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2684776T3 (en) * | 2013-01-18 | 2018-10-04 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as ROCK inhibitors |
US9783529B2 (en) | 2013-03-13 | 2017-10-10 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
US20150320706A1 (en) | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
EP3873474A4 (en) * | 2018-10-30 | 2022-07-13 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
EP3997070A4 (en) | 2019-07-02 | 2023-07-26 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
EP1148053A4 (en) * | 1999-01-26 | 2002-03-06 | Ono Pharmaceutical Co | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
WO2006036981A2 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
-
2008
- 2008-10-22 EP EP08843240A patent/EP2214667A2/en not_active Withdrawn
- 2008-10-22 WO PCT/US2008/011990 patent/WO2009054952A2/en active Application Filing
- 2008-10-22 AU AU2008317417A patent/AU2008317417A1/en not_active Abandoned
-
2010
- 2010-04-22 IL IL205299A patent/IL205299A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009054952A2 (en) | 2009-04-30 |
EP2214667A2 (en) | 2010-08-11 |
IL205299A0 (en) | 2010-12-30 |
WO2009054952A3 (en) | 2009-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8513433B2 (en) | Small molecule inhibitors of PARP activity | |
KR101444489B1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
US11504359B2 (en) | Antifibrotic compounds and uses thereof | |
US8680139B2 (en) | Anti-neoplastic compounds, compositions and methods | |
US20080058312A1 (en) | Modulators of hepatocyte growth factor/c-Met activity | |
EP2292227B1 (en) | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity | |
AU2003301224B2 (en) | Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity | |
AU2020257075B2 (en) | Methods and agents for treating disease | |
US20200071321A1 (en) | Methods and uses of compounds for treating disease | |
AU2008317417A1 (en) | Small molecule inhibitors of PARP activity | |
CA3073956A1 (en) | Vinylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors | |
JP2021533164A (en) | Imidazotetrazine compound | |
US20110098304A1 (en) | Small molecule inhibitors of PARP activity | |
US9597321B2 (en) | Antifibrotic compounds and uses thereof | |
CN100430392C (en) | Carbamoyl-type benzofuran derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |